Fas	B-protein
ligand	I-protein
induction	O
in	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
is	O
regulated	O
by	O
redox	O
through	O
a	O
calcineurin-nuclear	B-protein
factors	I-protein
of	O
activated	O
T	O
cell-dependent	O
pathway	O
.	O

Fas	B-protein
ligand	I-protein
(	O
FasL	B-protein
)	O
on	O
cytotoxic	O
lymphocytes	O
is	O
important	O
for	O
mediating	O
apoptosis	O
of	O
activated	O
lymphocytes	O
and	O
other	O
target	O
cells	O
.	O

We	O
have	O
reported	O
that	O
NK	O
cell	O
functions	O
,	O
such	O
as	O
proliferation	O
,	O
cell	O
death	O
,	O
and	O
killing	O
activity	O
,	O
are	O
subject	O
to	O
regulation	O
by	O
cellular	O
redox	O
status	O
.	O

Here	O
,	O
we	O
report	O
that	O
expression	O
of	O
FasL	B-protein
protein	I-protein
and	O
mRNA	B-RNA
in	O
activated	B-cell_type
NK	I-cell_type
cells	I-cell_type
is	O
also	O
regulated	O
by	O
redox	O
.	O

Ligation	O
of	O
CD16	B-protein
on	O
IL-2-preactivated	B-cell_type
NK	I-cell_type
cells	I-cell_type
resulted	O
in	O
reduction	O
of	O
intracellular	O
peroxide	O
level	O
as	O
well	O
as	O
induction	O
of	O
FasL	B-protein
expression	O
.	O

This	O
CD16	B-protein
-induced	O
FasL	B-protein
expression	O
was	O
suppressed	O
by	O
oxidative	O
stress	O
,	O
including	O
thiol	O
deprivation	O
or	O
treatment	O
with	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
.	O

Addition	O
of	O
thiol-reducing	O
compounds	O
,	O
such	O
as	O
L-cystine	O
,	O
2-ME	O
,	O
or	O
N-acetyl	O
cysteine	O
,	O
restored	O
FasL	B-protein
expression	O
.	O

These	O
data	O
suggest	O
that	O
CD16	B-protein
stimulation	O
requires	O
cellular	O
reducing	O
status	O
for	O
FasL	B-protein
induction	O
in	O
NK	B-cell_type
cells	I-cell_type
.	O

Because	O
FasL	O
gene	O
activation	O
following	O
CD16	B-protein
cross-linking	O
is	O
regulated	O
by	O
the	O
NF	B-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
,	O
we	O
examined	O
the	O
effect	O
of	O
oxidative	O
stresses	O
on	O
NFAT	B-protein
activation	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
revealed	O
that	O
both	O
thiol	O
insufficiency	O
and	O
H2O2	O
treatment	O
suppressed	O
DNA-binding	O
activity	O
of	O
NFAT	B-protein
and	O
that	O
addition	O
of	O
thiol-reducing	O
compounds	O
reversed	O
or	O
even	O
enhanced	O
it	O
.	O

Furthermore	O
,	O
these	O
oxidative	O
stresses	O
inhibited	O
activity	O
of	O
calcineurin	O
,	O
a	O
serine/	O
threonine	B-protein
phosphatase	I-protein
that	O
regulates	O
NFAT	B-protein
activation	O
.	O

These	O
results	O
suggest	O
that	O
suppression	O
of	O
calcineurin	B-protein
and	O
NFAT	B-protein
activation	O
is	O
a	O
mechanism	O
by	O
which	O
oxidative	O
stress	O
inhibits	O
FasL	B-protein
induction	O
in	O
activated	B-cell_type
NK	I-cell_type
cells	I-cell_type
and	O
further	O
support	O
the	O
hypothesis	O
that	O
thiol-reducing	O
compounds	O
might	O
be	O
required	O
for	O
maintenance	O
of	O
optimal	O
NK	O
functions	O
under	O
physiologic	O
oxidative	O
conditions	O
.	O

3	NULL
<	NULL
.	NULL

<	NULL
e	NULL
]	NULL
(	NULL
ap	NULL
)	NULL
D	NULL
3	NULL
Reporter	NULL
Cell	NULL
Lines	NULL
a	NULL
a	NULL
a	NULL
The	NULL
family	NULL
keeps	NULL
growing	NULL
Learn	NULL
more	NULL
As	NULL
Regulated	NULL
by	NULL
Redox	NULL
Through	NULL
a	NULL
--	NULL
-	NULL
-_	NULL
_	NULL
unology	NULL
Calcineurin-Nuclear	NULL
Factors	NULL
of	NULL
Activated	NULL
T	NULL
Cell-Dependent	NULL
Pathway	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Keizo	NULL
Furuke	NULL
,	NULL
Mitsuhiro	NULL
Shiraishi	NULL
,	NULL
Howard	NULL
S.	NULL
Mostowski	NULL
and	NULL
Eda	NULL
T.	NULL
Bloom	NULL
J	NULL
Immunol	NULL
1999	NULL
;	NULL
162:1988-1993	NULL
;	NULL
;	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/162/4/1988	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
44	NULL
articles	NULL
,	NULL
22	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/162/4/1988	NULL
.	NULL

full	NULL
#	NULL
ref-list-	NULL
1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
Fas	NULL
Ligand	NULL
Induction	NULL
in	NULL
Human	NULL
NK	NULL
Cells	NULL
Is	NULL
Regulated	NULL
by	NULL
Redox	NULL
Through	NULL
a	NULL
Calcineurin-Nuclear	NULL
Factors	NULL
of	NULL
Activated	NULL
T	NULL
Cell-Dependent	NULL
Pathway	NULL
Keizo	NULL
Furuke	NULL
,	NULL
Mitsuhiro	NULL
Shiraishi	NULL
,	NULL
Howard	NULL
S.	NULL
Mostowski	NULL
,	NULL
and	NULL
Eda	NULL
T.	NULL
Bloom	NULL
Fas	NULL
ligand	NULL
(	NULL
FasL	NULL
)	NULL
on	NULL
cytotoxic	NULL
lymphocytes	NULL
is	NULL
important	NULL
for	NULL
mediating	NULL
apoptosis	NULL
of	NULL
activated	NULL
lymphocytes	NULL
and	NULL
other	NULL
target	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
reported	NULL
that	NULL
NK	NULL
cell	NULL
functions	NULL
,	NULL
such	NULL
as	NULL
proliferation	NULL
,	NULL
cell	NULL
death	NULL
,	NULL
and	NULL
killing	NULL
activity	NULL
,	NULL
are	NULL
subject	NULL
to	NULL
regulation	NULL
by	NULL
cellular	NULL
redox	NULL
status	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
report	NULL
that	NULL
expression	NULL
of	NULL
FasL	NULL
protein	NULL
and	NULL
mRNA	NULL
in	NULL
activated	NULL
NK	NULL
cells	NULL
is	NULL
also	NULL
regulated	NULL
by	NULL
redox	NULL
.	NULL

Ligation	NULL
of	NULL
CD16	NULL
on	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
resulted	NULL
in	NULL
reduction	NULL
of	NULL
intracellular	NULL
peroxide	NULL
level	NULL
as	NULL
well	NULL
as	NULL
induction	NULL
of	NULL
FasL	NULL
expression	NULL
.	NULL

This	NULL
CD16-induced	NULL
FasL	NULL
expression	NULL
was	NULL
suppressed	NULL
by	NULL
oxidative	NULL
stress	NULL
,	NULL
including	NULL
thiol	NULL
deprivation	NULL
or	NULL
treatment	NULL
with	NULL
hydrogen	NULL
peroxide	NULL
(	NULL
H,0	NULL
,	NULL
)	NULL
.	NULL

Addition	NULL
of	NULL
thiol-reducing	NULL
compounds	NULL
,	NULL
such	NULL
as	NULL
L-cystine	NULL
,	NULL
2-ME	NULL
,	NULL
or	NULL
N-acetyl	NULL
cysteine	NULL
,	NULL
restored	NULL
FasL	NULL
expression	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
CD16	NULL
stimulation	NULL
requires	NULL
cellular	NULL
reducing	NULL
status	NULL
for	NULL
FasL	NULL
induction	NULL
in	NULL
NK	NULL
cells	NULL
.	NULL

Because	NULL
FasL	NULL
gene	NULL
activation	NULL
following	NULL
CD16	NULL
cross-linking	NULL
is	NULL
regulated	NULL
by	NULL
the	NULL
NF	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
oxidative	NULL
stresses	NULL
on	NULL
NFAT	NULL
activation	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
revealed	NULL
that	NULL
both	NULL
thiol	NULL
insufficiency	NULL
and	NULL
H	NULL
,	NULL
O	NULL
,	NULL
treatment	NULL
suppressed	NULL
DNA-binding	NULL
activity	NULL
of	NULL
NFAT	NULL
and	NULL
that	NULL
addition	NULL
of	NULL
thiol-reducing	NULL
compounds	NULL
reversed	NULL
or	NULL
even	NULL
enhanced	NULL
it	NULL
.	NULL

Furthermore	NULL
,	NULL
these	NULL
oxidative	NULL
stresses	NULL
inhibited	NULL
activity	NULL
of	NULL
calcineurin	NULL
,	NULL
a	NULL
serine/threonine	NULL
phosphatase	NULL
that	NULL
regulates	NULL
NFAT	NULL
activation	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
suppression	NULL
of	NULL
calcineurin	NULL
and	NULL
NFAT	NULL
activation	NULL
is	NULL
a	NULL
mechanism	NULL
by	NULL
which	NULL
oxidative	NULL
stress	NULL
inhibits	NULL
FasL	NULL
induction	NULL
in	NULL
activated	NULL
NK	NULL
cells	NULL
and	NULL
further	NULL
support	NULL
the	NULL
hypothesis	NULL
that	NULL
thiol-reducing	NULL
compounds	NULL
might	NULL
be	NULL
required	NULL
for	NULL
main	NULL
tenance	NULL
of	NULL
optimal	NULL
NK	NULL
functions	NULL
under	NULL
physiologic	NULL
oxidative	NULL
conditions	NULL
.	NULL

death	NULL
signal	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
upon	NULL
binding	NULL
with	NULL
its	NULL
natural	NULL
ligand	NULL
,	NULL
Fas	NULL
ligand	NULL
(	NULL
FasL	NULL
)	NULL
,	NULL
or	NULL
cross-linking	NULL
with	NULL
anti-Fas	NULL
IgM	NULL
mAb	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

CTL	NULL
and	NULL
NK	NULL
cells	NULL
are	NULL
known	NULL
to	NULL
express	NULL
FasL	NULL
during	NULL
activation	NULL
and	NULL
exert	NULL
granule-independent	NULL
cytotoxicity	NULL
via	NULL
Fas/FasL	NULL
interaction	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
growing	NULL
evidence	NULL
shows	NULL
that	NULL
cytotoxic	NULL
lymphocytes	NULL
treated	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
for	NULL
T	NULL
cells	NULL
undergo	NULL
apoptosis	NULL
following	NULL
homotypic	NULL
interaction	NULL
through	NULL
Fas	NULL
and	NULL
FasL	NULL
(	NULL
3-5	NULL
)	NULL
.	NULL

NK	NULL
cells	NULL
activated	NULL
with	NULL
cytokines	NULL
such	NULL
as	NULL
IL-2	NULL
exhibit	NULL
induction	NULL
of	NULL
FasL	NULL
and	NULL
increased	NULL
levels	NULL
of	NULL
Fas	NULL
on	NULL
their	NULL
cell	NULL
surface	NULL
and	NULL
undergo	NULL
apoptosis	NULL
by	NULL
homotypic	NULL
interaction	NULL
upon	NULL
cross-linking	NULL
of	NULL
€D16	NULL
(	NULL
FeyRIHN	NULL
)	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
Fas/FasL	NULL
system	NULL
is	NULL
also	NULL
considered	NULL
to	NULL
play	NULL
a	NULL
role	NULL
for	NULL
the	NULL
control	NULL
of	NULL
activated	NULL
cell	NULL
populations	NULL
in	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

A	NULL
number	NULL
of	NULL
signaling	NULL
events	NULL
mediating	NULL
FasL	NULL
gene	NULL
activation	NULL
have	NULL
been	NULL
investigated	NULL
.	NULL

ZAP-70	NULL
tyrosine	NULL
kinase	NULL
and	NULL
€D45	NULL
tyrosine	NULL
phosphatase	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
required	NULL
for	NULL
TCR-mediated	NULL
FasL	NULL
induction	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
FasL	NULL
expression	NULL
is	NULL
suppressed	NULL
by	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
(	NULL
9	NULL
)	NULL
,	NULL
glucocorticoid	NULL
hormone	NULL
,	NULL
I	NULL
T	NULL
as	NULL
(	NULL
APO-1/CD95	NULL
)	NULL
is	NULL
a	NULL
surface	NULL
receptor	NULL
that	NULL
transduces	NULL
a	NULL
Laboratory	NULL
of	NULL
Cellular	NULL
Immunology	NULL
,	NULL
Division	NULL
of	NULL
Cellular	NULL
and	NULL
Gene	NULL
Therapies	NULL
,	NULL
Center	NULL
for	NULL
Biologics	NULL
Evaluation	NULL
and	NULL
Research	NULL
,	NULL
Food	NULL
and	NULL
Drug	NULL
Administration	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
20892	NULL
Received	NULL
for	NULL
publication	NULL
July	NULL
21	NULL
,	NULL
1998	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
November	NULL
3	NULL
,	NULL
1998	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

*	NULL
Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Eda	NULL
T.	NULL
Bloom	NULL
,	NULL
Laboratory	NULL
of	NULL
Cellular	NULL
Immunology	NULL
(	NULL
HFM-518	NULL
)	NULL
,	NULL
Division	NULL
of	NULL
Cellular	NULL
and	NULL
Gene	NULL
Therapies	NULL
,	NULL
Center	NULL
for	NULL
Biologics	NULL
Evaluation	NULL
Research	NULL
,	NULL
Food	NULL
and	NULL
Drug	NULL
Administration	NULL
,	NULL
8800	NULL
Rockville	NULL
Pike	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
20892	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
bloom	NULL
@	NULL
cber.fda.gov	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
L	NULL
,	NULL
ligand	NULL
;	NULL
NFAT	NULL
,	NULL
NF	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
;	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A	NULL
;	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
,	NULL
RPMI	NULL
1640	NULL
medium	NULL
without	NULL
cystine	NULL
and	NULL
reduced	NULL
type	NULL
glu-tathione	NULL
;	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
,	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
in	NULL
which	NULL
L-cystine	NULL
has	NULL
been	NULL
replenished	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
GaM	NULL
,	NULL
goat	NULL
anti-mouse	NULL
IgG	NULL
;	NULL
G3PDH	NULL
,	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
;	NULL
MFI	NULL
mean	NULL
fluorescent	NULL
intensity	NULL
;	NULL
NAC	NULL
,	NULL
N-acetyl	NULL
cysteine	NULL
;	NULL
PE	NULL
,	NULL
phycoerythrin	NULL
;	NULL
ROS	NULL
,	NULL
reactive	NULL
oxygen	NULL
species	NULL
;	NULL
DCFH-DA	NULL
,	NULL
2',7'-dichlorofluorescin	NULL
diacetate	NULL
.	NULL

Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
1999	NULL
,	NULL
162	NULL
;	NULL
1988-1993.	NULL
or	NULL
retinoic	NULL
acid	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Transcription	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
NF	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
and	NULL
NF-KB	NULL
,	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
FasL	NULL
expression	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
8	NULL
,	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

Although	NULL
both	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
activity	NULL
of	NULL
transcriptional	NULL
factors	NULL
are	NULL
known	NULL
to	NULL
be	NULL
subject	NULL
to	NULL
regulation	NULL
by	NULL
cellular	NULL
redox	NULL
status	NULL
(	NULL
13	NULL
,	NULL
14	NULL
)	NULL
,	NULL
it	NULL
is	NULL
not	NULL
known	NULL
whether	NULL
cellular	NULL
redox	NULL
is	NULL
involved	NULL
in	NULL
regulating	NULL
FasL	NULL
expression	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
NK	NULL
cells	NULL
cultured	NULL
in	NULL
thiol-deficient	NULL
condi-tions	NULL
,	NULL
which	NULL
produces	NULL
decreased	NULL
levels	NULL
of	NULL
reduced	NULL
glutathione	NULL
,	NULL
are	NULL
unable	NULL
to	NULL
respond	NULL
to	NULL
IL-2	NULL
with	NULL
increased	NULL
proliferation	NULL
and	NULL
cytotoxicity	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
and	NULL
that	NULL
thiol	NULL
deprivation	NULL
also	NULL
facilitates	NULL
Fas-mediated	NULL
cell	NULL
death	NULL
in	NULL
NK	NULL
cells	NULL
(	NULL
17	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
prompted	NULL
us	NULL
to	NULL
examine	NULL
the	NULL
effect	NULL
of	NULL
cellular	NULL
redox	NULL
status	NULL
on	NULL
FasL	NULL
induction	NULL
in	NULL
NK	NULL
cells	NULL
treated	NULL
with	NULL
IL-2	NULL
and/or	NULL
anti-CD16	NULL
mAb	NULL
and	NULL
to	NULL
further	NULL
identify	NULL
an	NULL
underlying	NULL
mechanism	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Reagents	NULL
and	NULL
Abs	NULL
Human	NULL
rIL-2	NULL
was	NULL
provided	NULL
by	NULL
Amgen	NULL
(	NULL
Thousand	NULL
Oaks	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Metallopro-teinase	NULL
inhibitor	NULL
KB8301	NULL
was	NULL
purchased	NULL
from	NULL
PharMingen	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Anti-CD5	NULL
mAb	NULL
was	NULL
purified	NULL
from	NULL
ascites	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Anti-CD22	NULL
mAb	NULL
was	NULL
purchased	NULL
from	NULL
PharMingen	NULL
.	NULL

Anti-CD16	NULL
(	NULL
clone	NULL
3G8	NULL
)	NULL
,	NULL
anti-CD36	NULL
,	NULL
anti-CD56-phycoerythrin	NULL
(	NULL
PE	NULL
)	NULL
,	NULL
anti-CD16-PE	NULL
,	NULL
and	NULL
anti-CD14-PE	NULL
mAbs	NULL
were	NULL
purchased	NULL
from	NULL
Immunotech	NULL
(	NULL
Westbrook	NULL
,	NULL
ME	NULL
)	NULL
.	NULL

An-ti-CD16-FITC	NULL
mAb	NULL
and	NULL
anti-CD56	NULL
mAb	NULL
as	NULL
an	NULL
isotype	NULL
control	NULL
for	NULL
3G8	NULL
were	NULL
purchased	NULL
from	NULL
Becton	NULL
Dickinson	NULL
(	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Hydrogen	NULL
peroxide	NULL
(	NULL
H,0	NULL
,	NULL
)	NULL
,	NULL
2-ME	NULL
,	NULL
N-acetyl	NULL
cysteine	NULL
(	NULL
NAC	NULL
)	NULL
,	NULL
L-cystine	NULL
(	NULL
L-Cys	NULL
)	NULL
,	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
,	NULL
and	NULL
goat	NULL
anti-mouse	NULL
IgG	NULL
(	NULL
GaM	NULL
)	NULL
mAb	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
(	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

Cell	NULL
culture	NULL
and	NULL
isolation	NULL
Standard	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
contained	NULL
10	NULL
%	NULL
FCS	NULL
(	NULL
HyClone	NULL
Laboratories	NULL
,	NULL
Logan	NULL
,	NULL
UT	NULL
)	NULL
,	NULL
50	NULL
ug/ml	NULL
of	NULL
genta-micin	NULL
sulfate	NULL
,	NULL
and	NULL
2	NULL
mM	NULL
glutamine	NULL
.	NULL

RPMI	NULL
1640	NULL
medium	NULL
without	NULL
1-Cys	NULL
and	NULL
reduced	NULL
type	NULL
glutathione	NULL
(	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
medium	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
KEMP	NULL
Biotechnologies	NULL
(	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

FCS	NULL
for	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
medium	NULL
was	NULL
dia-lyzed	NULL
against	NULL
PBS	NULL
to	NULL
remove	NULL
small	NULL
m.w	NULL
.	NULL

compounds	NULL
,	NULL
including	NULL
thiols	NULL
.	NULL

CYS	NULL
(	NULL
+	NULL
)	NULL
medium	NULL
was	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
supplemented	NULL
with	NULL
200	NULL
uM	NULL
1-Cys	NULL
,	NULL
the	NULL
0022-1767/99/	NULL
$	NULL
02.00	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
concentration	NULL
normally	NULL
found	NULL
in	NULL
cell	NULL
culture	NULL
medium	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
for	NULL
12	NULL
h	NULL
in	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
or	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
medium	NULL
with	NULL
the	NULL
indicated	NULL
FCS	NULL
and	NULL
IL-2	NULL
supplementation	NULL
before	NULL
use	NULL
to	NULL
decrease	NULL
intracellular	NULL
thiol	NULL
levels	NULL
.	NULL

Total	NULL
amounts	NULL
of	NULL
protein	NULL
and	NULL
mRNA	NULL
,	NULL
as	NULL
well	NULL
as	NULL
cell	NULL
viability	NULL
(	NULL
>	NULL
90	NULL
%	NULL
)	NULL
,	NULL
did	NULL
not	NULL
differ	NULL
significantly	NULL
between	NULL
purified	NULL
NK	NULL
cells	NULL
cultured	NULL
for	NULL
12	NULL
h	NULL
in	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
or	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
medium	NULL
.	NULL

Human	NULL
NK	NULL
cells	NULL
were	NULL
purified	NULL
from	NULL
buffy	NULL
coats	NULL
from	NULL
healthy	NULL
donors	NULL
(	NULL
Blood	NULL
Bank	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
as	NULL
described	NULL
(	NULL
17	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
mononuclear	NULL
cells	NULL
were	NULL
obtained	NULL
by	NULL
centrifugation	NULL
over	NULL
lym-phocyte	NULL
separation	NULL
medium	NULL
(	NULL
Oreganon	NULL
Teknika	NULL
,	NULL
Durham	NULL
,	NULL
NC	NULL
)	NULL
and	NULL
treated	NULL
with	NULL
100	NULL
mg/10®	NULL
cells	NULL
of	NULL
sterilized	NULL
carbonyl	NULL
fron	NULL
(	NULL
Sigma	NULL
)	NULL
in	NULL
standard	NULL
RPMI	NULL
1640	NULL
medium	NULL
at	NULL
37°C	NULL
for	NULL
30	NULL
min	NULL
followed	NULL
by	NULL
exposure	NULL
to	NULL
a	NULL
magnetic	NULL
field	NULL
to	NULL
remove	NULL
monocytes	NULL
.	NULL

Cell	NULL
suspensions	NULL
were	NULL
centrifuged	NULL
over	NULL
47.5	NULL
%	NULL
Per-coll	NULL
to	NULL
obtain	NULL
low-density	NULL
large	NULL
granular	NULL
cells	NULL
.	NULL

NK-enriched	NULL
mononuclear	NULL
cells	NULL
were	NULL
further	NULL
treated	NULL
with	NULL
anti-CD5	NULL
,	NULL
anti-CD22	NULL
,	NULL
and	NULL
anti-CD36	NULL
mAbs	NULL
at	NULL
4°C	NULL
for	NULL
2-4	NULL
h	NULL
,	NULL
incubated	NULL
with	NULL
GaM-coated	NULL
magnet	NULL
beads	NULL
(	NULL
PerSeptive	NULL
Biosystems	NULL
,	NULL
Framingham	NULL
,	NULL
MA	NULL
)	NULL
at	NULL
4°C	NULL
for	NULL
30	NULL
min	NULL
and	NULL
exposed	NULL
to	NULL
a	NULL
magnetic	NULL
field	NULL
to	NULL
eliminate	NULL
residual	NULL
T	NULL
cells	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
monocytes	NULL
.	NULL

The	NULL
purity	NULL
of	NULL
NK	NULL
cells	NULL
(	NULL
CD16	NULL
*	NULL
and/or	NULL
CD56	NULL
*	NULL
)	NULL
in	NULL
each	NULL
experiment	NULL
was	NULL
always	NULL
85-95	NULL
%	NULL
as	NULL
assessed	NULL
by	NULL
FACScan	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
}	NULL
.	NULL

The	NULL
population	NULL
of	NULL
contaminating	NULL
T	NULL
cells	NULL
(	NULL
CDS56~	NULL
,	NULL
CD3	NULL
*	NULL
)	NULL
,	NULL
B	NULL
cells	NULL
(	NULL
CD20+*	NULL
)	NULL
,	NULL
or	NULL
monocytes/mac-rophages	NULL
(	NULL
CD14*	NULL
)	NULL
in	NULL
each	NULL
experiment	NULL
was	NULL
<	NULL
10	NULL
%	NULL
,	NULL
<	NULL
5	NULL
%	NULL
,	NULL
or	NULL
<	NULL
5	NULL
%	NULL
,	NULL
respectively	NULL
.	NULL

Flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
expression	NULL
of	NULL
FasL	NULL
and	NULL
intracellular	NULL
peroxide	NULL
levels	NULL
Quantitation	NULL
of	NULL
surface	NULL
FasL	NULL
expression	NULL
was	NULL
assessed	NULL
by	NULL
flow	NULL
cytometric	NULL
analysis	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
for	NULL
6	NULL
h	NULL
with	NULL
10	NULL
M	NULL
KB8301	NULL
(	NULL
PharMingen	NULL
)	NULL
,	NULL
a	NULL
metalloprotease	NULL
inhibitor	NULL
,	NULL
to	NULL
inhibit	NULL
FasL	NULL
release	NULL
(	NULL
18	NULL
)	NULL
,	NULL
washed	NULL
with	NULL
FACS	NULL
buffer	NULL
(	NULL
PBS	NULL
with	NULL
1	NULL
%	NULL
FCS	NULL
and	NULL
0.1	NULL
%	NULL
and	NULL
incubated	NULL
with	NULL
biotin-conjugated	NULL
anti-human	NULL
FasL	NULL
mAb	NULL
(	NULL
PharMingen	NULL
)	NULL
or	NULL
biotin-conjugated	NULL
mouse	NULL
IgG1	NULL
(	NULL
PharMingen	NULL
)	NULL
for	NULL
20	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

After	NULL
washing	NULL
with	NULL
FACS	NULL
buffer	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
streptavidin	NULL
PE	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
for	NULL
20	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

The	NULL
fluorescence	NULL
intensity	NULL
was	NULL
measured	NULL
by	NULL
FACScan	NULL
.	NULL

Intracellular	NULL
peroxide	NULL
levels	NULL
were	NULL
assayed	NULL
as	NULL
described	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
medium	NULL
with	NULL
5	NULL
uM	NULL
2',7'-dichlorofluorescin	NULL
diacetate	NULL
(	NULL
DCFH-DA	NULL
;	NULL
Molecular	NULL
Probes	NULL
,	NULL
Eugene	NULL
,	NULL
OR	NULL
)	NULL
for	NULL
15	NULL
min	NULL
at	NULL
37°C	NULL
following	NULL
the	NULL
indicated	NULL
treatments	NULL
and	NULL
harvested	NULL
for	NULL
flow	NULL
cytometry	NULL
.	NULL

In	NULL
experiments	NULL
designed	NULL
to	NULL
confirm	NULL
whether	NULL
NK	NULL
cells	NULL
contain	NULL
intracellular	NULL
peroxides	NULL
,	NULL
cells	NULL
were	NULL
stained	NULL
first	NULL
with	NULL
anti-CD56-	NULL
and	NULL
anti-CD16-PE	NULL
mAbs	NULL
to	NULL
identify	NULL
NK	NULL
cells	NULL
,	NULL
or	NULL
with	NULL
CD14-PE	NULL
mAb	NULL
to	NULL
identify	NULL
monocyte/macrophages	NULL
before	NULL
assay	NULL
for	NULL
peroxides	NULL
with	NULL
DCFH-DA	NULL
.	NULL

RT-PCR	NULL
analysis	NULL
of	NULL
FasL	NULL
and	NULL
IFN-y	NULL
mRNA	NULL
FasL	NULL
and	NULL
IFN-y	NULL
mRNA	NULL
expression	NULL
was	NULL
determined	NULL
by	NULL
RT-PCR	NULL
using	NULL
[	NULL
°°P	NULL
]	NULL
dCTP	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
17	NULL
,	NULL
20	NULL
)	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
cells	NULL
using	NULL
TRIzol	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
the	NULL
primer	NULL
pairs	NULL
in	NULL
this	NULL
experiment	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
human	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
(	NULL
G3PDH	NULL
;	NULL
used	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
)	NULL
,	NULL
5-GCT	NULL
CAG	NULL
ACA	NULL
CCA	NULL
TGG	NULL
GGA	NULL
AGG	NULL
T-3	NULL
'	NULL
,	NULL
5-GTG	NULL
GTG	NULL
CAG	NULL
GAG	NULL
GCA	NULL
TTG	NULL
CTG	NULL
A-3	NULL
'	NULL
;	NULL
human	NULL
FasL	NULL
,	NULL
5'-GTG	NULL
CCC	NULL
AGA	NULL
AGG	NULL
CCT	NULL
GGT	NULL
CAA	NULL
AGG-3	NULL
``	NULL
'	NULL
,	NULL
5'-TTG	NULL
CAA	NULL
GAT	NULL
TGA	NULL
CCC	NULL
CGG	NULL
AAG	NULL
TAT-3	NULL
'	NULL
;	NULL
and	NULL
human	NULL
IFN-y	NULL
,	NULL
5-GGA	NULL
CCC	NULL
ATA	NULL
TGT	NULL
AAA	NULL
AGA	NULL
AGC	NULL
AGA-3	NULL
'	NULL
,	NULL
CAC	NULL
TCT	NULL
CCT	NULL
CTT	NULL
TCC	NULL
AAT	NULL
TCT-3	NULL
'	NULL
.	NULL

Amplifications	NULL
were	NULL
performed	NULL
in	NULL
a	NULL
thermocycler	NULL
(	NULL
GeneAmp	NULL
PCR	NULL
system	NULL
9600	NULL
;	NULL
Perkin-Elmer	NULL
,	NULL
Norwalk	NULL
,	NULL
CT	NULL
)	NULL
as	NULL
follows	NULL
:	NULL
94°C	NULL
,	NULL
3	NULL
min	NULL
,	NULL
followed	NULL
by	NULL
21	NULL
(	NULL
G3PDH	NULL
)	NULL
or	NULL
35	NULL
(	NULL
FasL	NULL
and	NULL
IFN-y	NULL
)	NULL
cycles	NULL
(	NULL
94°C	NULL
,	NULL
1	NULL
min	NULL
;	NULL
57°C	NULL
,	NULL
1.5	NULL
min	NULL
;	NULL
72°C	NULL
,	NULL
2	NULL
min	NULL
)	NULL
.	NULL

Aliquots	NULL
of	NULL
each	NULL
amplification	NULL
were	NULL
analyzed	NULL
by	NULL
electrophoresis	NULL
in	NULL
5	NULL
%	NULL
acrylamide-Tris-borate	NULL
gels	NULL
.	NULL

The	NULL
lanes	NULL
were	NULL
normalized	NULL
to	NULL
G3PDH	NULL
mRNA	NULL
levels	NULL
as	NULL
described	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
by	NULL
Schreiber	NULL
et	NULL
al	NULL
.	NULL

(	NULL
21	NULL
)	NULL
from	NULL
cells	NULL
cultured	NULL
after	NULL
the	NULL
indicated	NULL
treatment	NULL
.	NULL

The	NULL
sequence	NULL
for	NULL
the	NULL
human	NULL
IL-2	NULL
distal	NULL
NFAT	NULL
site	NULL
(	NULL
GGA	NULL
GGA	NULL
AAA	NULL
ACT	NULL
GTT	NULL
TCA	NULL
TAC	NULL
AGA	NULL
AGG	NULL
(	NULL
22	NULL
)	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
to	NULL
measure	NULL
NFAT	NULL
activity	NULL
.	NULL

dsDNA	NULL
probe	NULL
was	NULL
synthesized	NULL
in	NULL
the	NULL
Center	NULL
for	NULL
Biologics	NULL
Evaluation	NULL
and	NULL
Research	NULL
Core	NULL
Facility	NULL
Services	NULL
(	NULL
CBER	NULL
,	NULL
Food	NULL
and	NULL
Drug	NULL
Administration	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

The	NULL
dsDNA	NULL
probe	NULL
was	NULL
end-labeled	NULL
with	NULL
[	NULL
y	NULL
``	NULL
P	NULL
]	NULL
JATP	NULL
(	NULL
3000	NULL
Ci/mmol	NULL
;	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
,	NULL
Uppsala	NULL
,	NULL
Swe-den	NULL
)	NULL
and	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

EMSA	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
23	NULL
)	NULL
with	NULL
some	NULL
modifications	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
nuclear	NULL
extracts	NULL
(	NULL
5	NULL
ug	NULL
per	NULL
reaction	NULL
volume	NULL
)	NULL
were	NULL
incubated	NULL
for	NULL
20	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
with	NULL
1	NULL
ug	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
and	NULL
0.5	NULL
ng	NULL
°°P-labeled	NULL
dsDNA	NULL
probe	NULL
in	NULL
20	NULL
ul	NULL
of	NULL
binding	NULL
buffer	NULL
1989	NULL
60	NULL
-O-	NULL
_	NULL
CD56	NULL
(	NULL
+	NULL
)	NULL
FasL	NULL
50	NULL
-A-	NULL
CDi6	NULL
(	NULL
@	NULL
+M¥IgGi	NULL
40	NULL
T	NULL
-o-	NULL
cDisoyrat	NULL
MFI	NULL
30	NULL
20	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
Time	NULL
after	NULL
CD16	NULL
stimulation	NULL
(	NULL
h	NULL
)	NULL
FIGURE	NULL
1	NULL
.	NULL

Time	NULL
course	NULL
of	NULL
CD16-induced	NULL
FasL	NULL
expression	NULL
in	NULL
IL-2-pretreated	NULL
NK	NULL
cells	NULL
.	NULL

Purified	NULL
NK	NULL
cells	NULL
were	NULL
cultured	NULL
with	NULL
100	NULL
U/ml	NULL
of	NULL
rIL-2	NULL
for	NULL
3	NULL
days	NULL
,	NULL
treated	NULL
with	NULL
10	NULL
pg/ml	NULL
of	NULL
anti-CD16	NULL
or	NULL
an	NULL
isotype	NULL
control	NULL
anti-CD56	NULL
mAb	NULL
plus	NULL
10	NULL
pg/ml	NULL
of	NULL
GaM	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
periods	NULL
,	NULL
and	NULL
harvested	NULL
for	NULL
flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
FasL	NULL
expression	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
means	NULL
+	NULL
SD	NULL
of	NULL
the	NULL
MFI	NULL
obtained	NULL
on	NULL
NK	NULL
cells	NULL
from	NULL
three	NULL
different	NULL
donors	NULL
.	NULL

(	NULL
10	NULL
mM	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
50	NULL
mM	NULL
NaCl	NULL
,	NULL
30	NULL
mM	NULL
KCI	NULL
,	NULL
5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
and	NULL
0.05	NULL
%	NULL
Nonidet	NULL
P-40	NULL
)	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
stopped	NULL
with	NULL
2	NULL
ul	NULL
of	NULL
0.1	NULL
%	NULL
bromophenol	NULL
blue	NULL
,	NULL
followed	NULL
by	NULL
electrophoresis	NULL
on	NULL
5	NULL
%	NULL
polyacryl-amide	NULL
gels	NULL
in	NULL
0.25	NULL
%	NULL
Tris-buffered	NULL
EDTA	NULL
(	NULL
pH	NULL
8.4	NULL
)	NULL
under	NULL
nondenaturing	NULL
conditions	NULL
.	NULL

An	NULL
unlabeled	NULL
cold	NULL
probe	NULL
(	NULL
5	NULL
ng	NULL
)	NULL
was	NULL
added	NULL
at	NULL
the	NULL
beginning	NULL
of	NULL
the	NULL
reaction	NULL
as	NULL
a	NULL
competitor	NULL
.	NULL

For	NULL
supershift	NULL
,	NULL
1	NULL
pl	NULL
of	NULL
antisera	NULL
against	NULL
murine	NULL
NFAT1	NULL
(	NULL
Upstate	NULL
Biotechnology	NULL
,	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
which	NULL
cross-reacts	NULL
with	NULL
human	NULL
NFAT1	NULL
,	NULL
was	NULL
added	NULL
to	NULL
nuclear	NULL
extracts	NULL
and	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
30	NULL
min	NULL
before	NULL
the	NULL
binding	NULL
reaction	NULL
.	NULL

Calcineurin	NULL
assay	NULL
Calcineurin	NULL
activity	NULL
was	NULL
assayed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Hypotonic	NULL
lysates	NULL
from	NULL
10	NULL
``	NULL
purified	NULL
NK	NULL
cells	NULL
were	NULL
assessed	NULL
following	NULL
the	NULL
indicated	NULL
treatments	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
dephosphorylate	NULL
a	NULL
*°P-serine-labeled	NULL
19-amino	NULL
acid	NULL
peptide	NULL
substrate	NULL
(	NULL
Sigma	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
okadaic	NULL
acid	NULL
(	NULL
Sig-ma	NULL
)	NULL
,	NULL
a	NULL
phosphatase	NULL
type	NULL
1	NULL
and	NULL
2A	NULL
inhibitor	NULL
.	NULL

Reaction	NULL
mixtures	NULL
contained	NULL
20	NULL
ul	NULL
of	NULL
lysates	NULL
,	NULL
500	NULL
nM	NULL
okadaic	NULL
acid	NULL
,	NULL
5	NULL
M	NULL
``	NULL
P-labeled	NULL
phosphopeptide	NULL
,	NULL
and	NULL
40	NULL
pl	NULL
of	NULL
assay	NULL
buffer	NULL
containing	NULL
20	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
,	NULL
100	NULL
mM	NULL
NaCl	NULL
,	NULL
6	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.1	NULL
mM	NULL
CaCl	NULL
,	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
0.1	NULL
mg/m	NULL
!	NULL

of	NULL
BSA	NULL
.	NULL

After	NULL
15	NULL
min	NULL
at	NULL
30°C	NULL
,	NULL
reactions	NULL
were	NULL
terminated	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
0.5	NULL
ml	NULL
100	NULL
mM	NULL
potassium	NULL
phosphate	NULL
buffer	NULL
(	NULL
pH	NULL
7.0	NULL
)	NULL
containing	NULL
5	NULL
%	NULL
trichloroacetic	NULL
acid	NULL
.	NULL

Free	NULL
inorganic	NULL
phosphate	NULL
was	NULL
isolated	NULL
using	NULL
a	NULL
Dowex	NULL
cation-exchange	NULL
resin	NULL
(	NULL
AGSOW-X8	NULL
100-200	NULL
mesh	NULL
;	NULL
Bio-Rad	NULL
,	NULL
Hercules	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
quanti-tated	NULL
by	NULL
scintillation	NULL
counting	NULL
.	NULL

Variation	NULL
between	NULL
duplicates	NULL
was	NULL
<	NULL
10	NULL
%	NULL
.	NULL

The	NULL
number	NULL
of	NULL
picomoles	NULL
of	NULL
phosphate	NULL
released	NULL
was	NULL
calculated	NULL
by	NULL
using	NULL
the	NULL
sp	NULL
.	NULL

act	NULL
.	NULL

(	NULL
cpm	NULL
in	NULL
300	NULL
pmol	NULL
*°P-labeled	NULL
phosphopeptide	NULL
)	NULL
measured	NULL
on	NULL
the	NULL
day	NULL
of	NULL
the	NULL
assay	NULL
.	NULL

The	NULL
protein	NULL
content	NULL
of	NULL
cell	NULL
lysates	NULL
was	NULL
determined	NULL
with	NULL
a	NULL
Bio-Rad	NULL
Protein	NULL
Assay	NULL
Kit	NULL
,	NULL
and	NULL
calcineurin	NULL
activity	NULL
was	NULL
expressed	NULL
as	NULL
picomoles	NULL
of	NULL
released	NULL
°°P	NULL
per	NULL
minute	NULL
per	NULL
milligram	NULL
of	NULL
lysate	NULL
protein	NULL
.	NULL

Results	NULL
Time	NULL
course	NULL
of	NULL
increase	NULL
in	NULL
FasL	NULL
expression	NULL
in	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
by	NULL
anti-CD16	NULL
Ab	NULL
It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
FasL	NULL
mRNA	NULL
can	NULL
be	NULL
detected	NULL
in	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
within	NULL
6	NULL
h	NULL
following	NULL
treatment	NULL
with	NULL
anti-CD16	NULL
Ab	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
first	NULL
examined	NULL
the	NULL
time	NULL
course	NULL
of	NULL
cell	NULL
surface	NULL
FasL	NULL
protein	NULL
expression	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
,	NULL
on	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
following	NULL
ligation	NULL
of	NULL
CD16	NULL
.	NULL

NK	NULL
cells	NULL
cultured	NULL
with	NULL
IL-2	NULL
for	NULL
3	NULL
days	NULL
expressed	NULL
FasL	NULL
only	NULL
weakly	NULL
(	NULL
mean	NULL
fluorescent	NULL
intensity	NULL
(	NULL
MFI	NULL
)	NULL
<	NULL
10	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
however	NULL
,	NULL
FasL	NULL
expression	NULL
was	NULL
increased	NULL
within	NULL
6	NULL
h	NULL
and	NULL
peaked	NULL
between	NULL
6-24	NULL
h	NULL
following	NULL
addition	NULL
of	NULL
anti-CD16	NULL
mAb	NULL
,	NULL
although	NULL
time	NULL
points	NULL
of	NULL
the	NULL
peak	NULL
FasL	NULL
expression	NULL
varied	NULL
among	NULL
cells	NULL
from	NULL
individual	NULL
donors	NULL
.	NULL

We	NULL
confirmed	NULL
that	NULL
the	NULL
fluorescence	NULL
intensity	NULL
was	NULL
specific	NULL
for	NULL
FasL	NULL
using	NULL
biotin-conjugated	NULL
mouse	NULL
IgG1	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
FasL	NULL
was	NULL
specific	NULL
for	NULL
CD16	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
1990	NULL
e	NULL
Co	NULL
5a	NULL
,	NULL
&	NULL
_	NULL
j	NULL
8	NULL
bes	NULL
E	NULL
9—5	NULL
7	NULL
%	NULL
b	NULL
754	NULL
J	NULL
.	NULL

w	NULL
0	NULL
8	NULL
~s	NULL
.	NULL

§	NULL
o	NULL
24	NULL
-	NULL
&	NULL
aso	NULL
a	NULL
k	NULL
F	NULL
Bein	NULL
.	NULL

009	NULL
5	NULL
,	NULL
3	NULL
f	NULL
:	NULL
10°	NULL
10	NULL
)	NULL
102	NULL
10°	NULL
104	NULL
DCFH-DA	NULL
t	NULL
cois	NULL
H2oz	NULL
a	NULL
]	NULL
CONTROL	NULL
ﬂ	NULL
“	NULL
CYS	NULL
(	NULL
)	NULL
Cell	NULL
Counts	NULL
so	NULL
.	NULL

\	NULL
10	NULL
£	NULL
Mik	NULL
Dou	NULL
01	NULL
10°	NULL
10	NULL
Fluorescent	NULL
Intensity	NULL
FIGURE	NULL
2	NULL
.	NULL

-	NULL
A	NULL
,	NULL
Double	NULL
staining	NULL
of	NULL
purified	NULL
NK	NULL
cell	NULL
population	NULL
with	NULL
anti-CD56-	NULL
and	NULL
anti-CD16-PE	NULL
mAbs	NULL
or	NULL
with	NULL
anti-CD14-PE	NULL
mAb	NULL
in	NULL
combination	NULL
with	NULL
DCFH-DA	NULL
assay	NULL
for	NULL
peroxides	NULL
.	NULL

The	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
experiments	NULL
using	NULL
cells	NULL
from	NULL
three	NULL
different	NULL
donors	NULL
and	NULL
demonstrate	NULL
that	NULL
the	NULL
populations	NULL
of	NULL
CD56	NULL
*	NULL
and/or	NULL
CD16*	NULL
NK	NULL
cells	NULL
and	NULL
CD14*	NULL
monocyte/	NULL
macrophages	NULL
were	NULL
both	NULL
positive	NULL
for	NULL
peroxide	NULL
staining	NULL
and	NULL
represent	NULL
87	NULL
%	NULL
and	NULL
3	NULL
%	NULL
of	NULL
the	NULL
cell	NULL
populations	NULL
,	NULL
respectively	NULL
.	NULL

B	NULL
,	NULL
Effects	NULL
of	NULL
treatment	NULL
with	NULL
anti-CD16	NULL
mAb	NULL
or	NULL
H	NULL
,	NULL
O	NULL
,	NULL
or	NULL
culture	NULL
in	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
medium	NULL
on	NULL
intracellular	NULL
peroxide	NULL
levels	NULL
in	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
.	NULL

Purified	NULL
NK	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100	NULL
U/ml	NULL
of	NULL
IL-2	NULL
in	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
medium	NULL
for	NULL
72	NULL
h	NULL
(	NULL
labeled	NULL
as	NULL
CONTROL	NULL
)	NULL
,	NULL
cultured	NULL
in	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
medium	NULL
for	NULL
60	NULL
h	NULL
and	NULL
in	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
medium	NULL
for	NULL
an	NULL
additional	NULL
12	NULL
h	NULL
(	NULL
labeled	NULL
as	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
)	NULL
,	NULL
or	NULL
cultured	NULL
in	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
medium	NULL
for	NULL
70	NULL
h	NULL
and	NULL
treated	NULL
with	NULL
10	NULL
pg/ml	NULL
of	NULL
anti-CD16	NULL
plus	NULL
10	NULL
ug/ml	NULL
of	NULL
GaM	NULL
(	NULL
labeled	NULL
as	NULL
CD16	NULL
)	NULL
or	NULL
with	NULL
100	NULL
uM	NULL
H	NULL
,	NULL
O	NULL
;	NULL
(	NULL
labeled	NULL
as	NULL
H	NULL
;	NULL
,0	NULL
,	NULL
)	NULL
in	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
medium	NULL
for	NULL
an	NULL
additional	NULL
2	NULL
h.	NULL
Intracellular	NULL
peroxide	NULL
levels	NULL
measured	NULL
by	NULL
flow	NULL
cytometry	NULL
were	NULL
reduced	NULL
by	NULL
anti-CD16	NULL
mAb	NULL
treatment	NULL
but	NULL
increased	NULL
by	NULL
addition	NULL
of	NULL
exogenous	NULL
H	NULL
,	NULL
O	NULL
;	NULL
or	NULL
thiol	NULL
deprivation	NULL
.	NULL

A	NULL
representative	NULL
of	NULL
four	NULL
independent	NULL
experiments	NULL
is	NULL
presented	NULL
.	NULL

cross-linking	NULL
because	NULL
anti-€CD56	NULL
mAb	NULL
,	NULL
an	NULL
isotype	NULL
control	NULL
for	NULL
anti-CD16	NULL
mAb	NULL
,	NULL
did	NULL
not	NULL
show	NULL
any	NULL
alteration	NULL
in	NULL
FasL	NULL
expression	NULL
.	NULL

Ligation	NULL
of	NULL
CD16	NULL
decreased	NULL
intracellular	NULL
peroxide	NULL
level	NULL
in	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
Intracellular	NULL
peroxide	NULL
levels	NULL
are	NULL
known	NULL
to	NULL
reflect	NULL
the	NULL
generation	NULL
of	NULL
reactive	NULL
oxygen	NULL
species	NULL
(	NULL
ROS	NULL
)	NULL
(	NULL
25	NULL
)	NULL
and	NULL
to	NULL
be	NULL
increased	NULL
under	NULL
conditions	NULL
of	NULL
oxidative	NULL
stress	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
next	NULL
measured	NULL
intracellular	NULL
peroxide	NULL
levels	NULL
as	NULL
an	NULL
indicator	NULL
of	NULL
whether	NULL
CD16	NULL
ligation	NULL
affects	NULL
intracellular	NULL
redox	NULL
status	NULL
in	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
.	NULL

We	NULL
found	NULL
that	NULL
intracellular	NULL
peroxides	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
CD56	NULL
*	NULL
and/or	NULL
CD16*	NULL
NK	NULL
cells	NULL
,	NULL
which	NULL
represented	NULL
>	NULL
85	NULL
%	NULL
of	NULL
the	NULL
cell	NULL
population	NULL
,	NULL
and	NULL
in	NULL
CD14*	NULL
monocyte/macrophages	NULL
,	NULL
representing	NULL
only	NULL
3	NULL
%	NULL
of	NULL
the	NULL
cell	NULL
population	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
intracellular	NULL
peroxide	NULL
was	NULL
strongly	NULL
reduced	NULL
following	NULL
treatment	NULL
with	NULL
anti-CD16	NULL
mAb	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
,	NULL
although	NULL
no	NULL
effect	NULL
was	NULL
seen	NULL
with	NULL
anti-CD56	NULL
mAb	NULL
of	NULL
the	NULL
same	NULL
isotype	NULL
as	NULL
the	NULL
anti-CD16	NULL
mAb	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
either	NULL
culture	NULL
in	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
medium	NULL
for	NULL
12	NULL
h	NULL
or	NULL
treatment	NULL
with	NULL
100	NULL
mM	NULL
H	NULL
,	NULL
O	NULL
,	NULL
for	NULL
2	NULL
h	NULL
increased	NULL
contents	NULL
of	NULL
intracellular	NULL
peroxides	NULL
in	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
ROS	NULL
production	NULL
is	NULL
suppressed	NULL
or	NULL
levels	NULL
are	NULL
quenched	NULL
following	NULL
CD16	NULL
cross-linking	NULL
in	NULL
NK	NULL
cells	NULL
,	NULL
and	NULL
that	NULL
both	NULL
thiol	NULL
deprivation	NULL
and	NULL
H	NULL
,	NULL
O	NULL
,	NULL
treatment	NULL
result	NULL
in	NULL
oxidative	NULL
stress	NULL
through	NULL
increasing	NULL
intracellular	NULL
ROS	NULL
levels	NULL
.	NULL

REDOX	NULL
CONTROL	NULL
OF	NULL
Fas	NULL
LIGAND	NULL
EXPRESSION	NULL
IN	NULL
HUMAN	NULL
NK	NULL
CELLS	NULL
A	NULL
so	NULL
40	NULL
_	NULL
T	NULL
-|-30	NULL
&	NULL
T	NULL
20	NULL
-	NULL
|J	NULL
I	NULL
10	NULL
~	NULL
o	NULL
_	NULL
0	NULL
-	NULL
O4	NULL
0d	NULL
10	NULL
_	NULL
100	NULL
H202	NULL
(	NULL
uM	NULL
)	NULL
B	NULL
MFI	NULL
m	NULL
1	NULL
NAC	NULL
05205	NULL
C	NULL
C	NULL
FIGURE	NULL
3	NULL
.	NULL

Effects	NULL
of	NULL
H	NULL
,	NULL
O	NULL
;	NULL
treatment	NULL
(	NULL
A	NULL
)	NULL
or	NULL
thiol	NULL
deprivation	NULL
and	NULL
addition	NULL
of	NULL
thiol	NULL
reducing	NULL
compounds	NULL
(	NULL
B	NULL
)	NULL
on	NULL
CD16-induced	NULL
FasL	NULL
expression	NULL
.	NULL

A	NULL
,	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
10	NULL
pg/ml	NULL
of	NULL
anti-CD16	NULL
plus	NULL
10	NULL
pg/ml	NULL
of	NULL
GaM	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
H	NULL
,	NULL
O	NULL
;	NULL
for	NULL
12	NULL
h.	NULL
B	NULL
,	NULL
IL-2-pretreated	NULL
NK	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
or	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
medium	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
50	NULL
uM	NULL
2-ME	NULL
or	NULL
10	NULL
mM	NULL
NAC	NULL
with	NULL
10	NULL
pg/ml	NULL
of	NULL
anti-CD16	NULL
or	NULL
anti-CD56	NULL
mAb	NULL
plus	NULL
10	NULL
ug/tal	NULL
of	NULL
GaM	NULL
for	NULL
12	NULL
h.	NULL
FasL	NULL
expression	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
was	NULL
suppressed	NULL
by	NULL
oxidative	NULL
stress	NULL
,	NULL
including	NULL
thiol	NULL
deprivation	NULL
or	NULL
H	NULL
,	NULL
O	NULL
,	NULL
treatment	NULL
,	NULL
and	NULL
restored	NULL
by	NULL
addition	NULL
of	NULL
thiol-reducing	NULL
compounds	NULL
,	NULL
such	NULL
as	NULL
1-Cys	NULL
,	NULL
2-ME	NULL
,	NULL
or	NULL
NAC	NULL
.	NULL

Data	NULL
are	NULL
MFI	NULL
+	NULL
SD	NULL
from	NULL
three	NULL
different	NULL
donors	NULL
.	NULL

Inhibition	NULL
of	NULL
FasL	NULL
induction	NULL
in	NULL
anti-CD16-treated	NULL
NK	NULL
cells	NULL
by	NULL
H,0	NULL
,	NULL
treatment	NULL
or	NULL
by	NULL
thiol	NULL
deprivation	NULL
To	NULL
evaluate	NULL
the	NULL
effects	NULL
of	NULL
oxidative	NULL
stress	NULL
on	NULL
FasL	NULL
expression	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
effect	NULL
of	NULL
H	NULL
,	NULL
O	NULL
;	NULL
treatment	NULL
on	NULL
FasL	NULL
cell	NULL
surface	NULL
expression	NULL
in	NULL
anti-CD16-treated	NULL
NK	NULL
cells	NULL
.	NULL

When	NULL
IL-2-pretreated	NULL
NK	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
0.1-100	NULL
uM	NULL
H	NULL
,	NULL
O	NULL
,	NULL
for	NULL
12	NULL
h	NULL
,	NULL
FasL	NULL
expression	NULL
induced	NULL
by	NULL
anti-CD16	NULL
mAb	NULL
was	NULL
reduced	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

Cell	NULL
viability	NULL
was	NULL
not	NULL
significantly	NULL
affected	NULL
at	NULL
the	NULL
same	NULL
concentrations	NULL
of	NULL
H	NULL
,	NULL
O	NULL
,	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
clarify	NULL
whether	NULL
cellular	NULL
redox	NULL
status	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
FasL	NULL
induction	NULL
following	NULL
CD16	NULL
cross-linking	NULL
,	NULL
we	NULL
next	NULL
assessed	NULL
the	NULL
effects	NULL
on	NULL
FasL	NULL
induction	NULL
of	NULL
manipulating	NULL
cellular	NULL
redox	NULL
status	NULL
in	NULL
activated	NULL
NK	NULL
cells	NULL
using	NULL
thiol	NULL
deprivation	NULL
with	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
medium	NULL
or	NULL
by	NULL
adding	NULL
back	NULL
thiol-reducing	NULL
compounds	NULL
.	NULL

NK	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
IL-2	NULL
in	NULL
standard	NULL
medium	NULL
for	NULL
60	NULL
h	NULL
,	NULL
followed	NULL
by	NULL
culture	NULL
in	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
or	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
medium	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-CD16	NULL
or	NULL
anti-CD56	NULL
mAb	NULL
for	NULL
an	NULL
additional	NULL
12	NULL
h.	NULL
As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
FasL	NULL
induction	NULL
following	NULL
ligation	NULL
of	NULL
CD16	NULL
was	NULL
completely	NULL
inhibited	NULL
in	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
medium	NULL
.	NULL

No	NULL
alteration	NULL
of	NULL
FasL	NULL
expression	NULL
by	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
was	NULL
observed	NULL
in	NULL
anti-CD56-treated	NULL
NK	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
decrease	NULL
in	NULL
FasL	NULL
expression	NULL
was	NULL
completely	NULL
reversed	NULL
by	NULL
addition	NULL
to	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
medium	NULL
of	NULL
200	NULL
uM	NULL
1-Cys	NULL
,	NULL
50	NULL
uM	NULL
2-ME	NULL
,	NULL
or	NULL
10	NULL
mM	NULL
NAC	NULL
,	NULL
which	NULL
are	NULL
thiol-reducing	NULL
compounds	NULL
that	NULL
we	NULL
have	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
CD56	NULL
+	NULL
z	NULL
«	NULL
s	NULL
®	NULL
&	NULL
is	NULL
CD16	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+o	NULL
+	NULL
H20z	NULL
-	NULL
-	NULL
-	NULL
10	NULL
-	NULL
100	NULL
_	NULL
-	NULL
-	NULL
(	NULL
uM	NULL
)	NULL
CYS	NULL
+o	NULL
o	NULL
+	NULL
+	NULL
+	NULL
-	NULL
-	NULL
E	NULL
2-ME	NULL
_	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
ee	NULL
NAC	NULL
_	NULL
-	NULL
-	NULL
-	NULL
f	NULL
s	NULL
-o	NULL
¢	NULL
FasL	NULL
guam	NULL
maas	NULL
ume	NULL
503	NULL
b.p	NULL
.	NULL

wis	NULL
un	NULL
wn	NULL
wh	NULL
on	NULL
cm	NULL
1210.0	NULL
.	NULL

G3PDH	NULL
wee	NULL
wee	NULL
wane	NULL
wass	NULL
mae	NULL
wease	NULL
whee	NULL
470	NULL
b.p	NULL
.	NULL

IFNy	NULL
&	NULL
125	NULL
Z	NULL
100	NULL
E	NULL
4	NULL
75	NULL
©	NULL
501	NULL
B	NULL
3	NULL
2s	NULL
c	NULL
6	NULL
FIGURE	NULL
4	NULL
.	NULL

CD16-induced	NULL
FasL	NULL
mRNA	NULL
expression	NULL
was	NULL
suppressed	NULL
by	NULL
thiol	NULL
deprivation	NULL
or	NULL
H	NULL
,	NULL
O	NULL
,	NULL
treatment	NULL
and	NULL
restored	NULL
by	NULL
addition	NULL
of	NULL
thiol	NULL
compounds	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
mRNA	NULL
encoding	NULL
for	NULL
IFN-y	NULL
was	NULL
augmented	NULL
by	NULL
cross-linking	NULL
of	NULL
CD16	NULL
,	NULL
but	NULL
this	NULL
level	NULL
was	NULL
unaffected	NULL
by	NULL
manipulation	NULL
of	NULL
redox	NULL
conditions	NULL
.	NULL

IL-2-preactivated	NULL
NK	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
or	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
medium	NULL
for	NULL
9	NULL
h	NULL
,	NULL
then	NULL
treated	NULL
as	NULL
indicated	NULL
(	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
for	NULL
3	NULL
h.	NULL
RT-PCR	NULL
analysis	NULL
for	NULL
FasL	NULL
,	NULL
IFN-y	NULL
,	NULL
or	NULL
G3PDH	NULL
mRNA	NULL
is	NULL
depicted	NULL
and	NULL
is	NULL
a	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Quantitative	NULL
presentation	NULL
(	NULL
percentage	NULL
of	NULL
NFAT	NULL
DNA-binding	NULL
activity	NULL
in	NULL
each	NULL
sample	NULL
compared	NULL
with	NULL
the	NULL
sample	NULL
treated	NULL
with	NULL
anti-CD16	NULL
in	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
medium	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
is	NULL
also	NULL
shown	NULL
using	NULL
data	NULL
obtained	NULL
by	NULL
PhosphorImage	NULL
(	NULL
Molecular	NULL
Dynam-ics	NULL
,	NULL
Sunnyvale	NULL
,	NULL
CA	NULL
)	NULL
analysis	NULL
.	NULL

shown	NULL
to	NULL
increase	NULL
intracellular	NULL
reduced	NULL
type	NULL
glutathione	NULL
in	NULL
NK	NULL
cells	NULL
(	NULL
15	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
findings	NULL
show	NULL
that	NULL
oxidative	NULL
stress	NULL
may	NULL
generally	NULL
suppress	NULL
FasL	NULL
induction	NULL
in	NULL
activated	NULL
NK	NULL
cells	NULL
and	NULL
that	NULL
reducing	NULL
conditions	NULL
are	NULL
necessary	NULL
for	NULL
optimal	NULL
FasL	NULL
expression	NULL
.	NULL

Suppression	NULL
of	NULL
FasL	NULL
mRNA	NULL
levels	NULL
and	NULL
NFAT	NULL
transcription	NULL
factor	NULL
activity	NULL
in	NULL
anti-CD16-treated	NULL
NK	NULL
cells	NULL
by	NULL
thiol	NULL
deprivation	NULL
or	NULL
H	NULL
,	NULL
O	NULL
;	NULL
treatment	NULL
We	NULL
next	NULL
asked	NULL
whether	NULL
FasL	NULL
mRNA	NULL
expression	NULL
was	NULL
also	NULL
suppressed	NULL
by	NULL
oxidative	NULL
stress	NULL
.	NULL

Semiquantitative	NULL
RT-PCR	NULL
revealed	NULL
that	NULL
the	NULL
increase	NULL
in	NULL
FasL	NULL
mRNA	NULL
following	NULL
treatment	NULL
with	NULL
anti-CD16	NULL
mAb	NULL
was	NULL
completely	NULL
suppressed	NULL
by	NULL
thiol	NULL
deprivation	NULL
or	NULL
H	NULL
,	NULL
O	NULL
,	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

The	NULL
diminished	NULL
FasL	NULL
mRNA	NULL
levels	NULL
induced	NULL
by	NULL
thiol	NULL
deprivation	NULL
were	NULL
reversed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
1-Cys	NULL
,	NULL
2-ME	NULL
,	NULL
or	NULL
NAC	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
augmentation	NULL
of	NULL
IFN-y	NULL
mRNA	NULL
levels	NULL
induced	NULL
by	NULL
CD16	NULL
cross-linking	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
manipulations	NULL
of	NULL
cellular	NULL
redox	NULL
status	NULL
,	NULL
including	NULL
thiol	NULL
deprivation	NULL
,	NULL
H	NULL
,	NULL
O	NULL
,	NULL
treatment	NULL
,	NULL
or	NULL
addition	NULL
of	NULL
2-ME	NULL
or	NULL
NAC	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
events	NULL
downstream	NULL
of	NULL
CD16	NULL
activation	NULL
are	NULL
not	NULL
uniformly	NULL
subject	NULL
to	NULL
regulation	NULL
by	NULL
redox	NULL
.	NULL

Because	NULL
the	NULL
transcription	NULL
factor	NULL
NFAT	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
participate	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
FasL	NULL
expression	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
11	NULL
,	NULL
27	NULL
)	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
either	NULL
thiol	NULL
deprivation	NULL
or	NULL
H	NULL
,	NULL
O	NULL
,	NULL
treatment	NULL
on	NULL
DNA-binding	NULL
activity	NULL
of	NULL
NFAT	NULL
in	NULL
anti-CD16-treated	NULL
NK	NULL
cells	NULL
as	NULL
determined	NULL
by	NULL
EMSA	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
activation	NULL
of	NULL
NFAT	NULL
following	NULL
ligation	NULL
of	NULL
CD16	NULL
was	NULL
inhibited	NULL
by	NULL
treatment	NULL
with	NULL
H	NULL
,	NULL
O	NULL
;	NULL
in	NULL
a	NULL
dose	NULL
dependent	NULL
manner	NULL
and	NULL
completely	NULL
suppressed	NULL
by	NULL
thiol	NULL
depletion	NULL
.	NULL

The	NULL
suppressed	NULL
DNA-binding	NULL
activity	NULL
of	NULL
NFAT	NULL
by	NULL
thiol	NULL
deprivation	NULL
was	NULL
restored	NULL
by	NULL
addition	NULL
of	NULL
1.-Cys	NULL
or	NULL
NAC	NULL
and	NULL
1991	NULL
10	NULL
uM	NULL
H202	NULL
100	NULL
uM	NULL
H207	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
+	NULL
NAC	NULL
CDSé	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
Cys	NULL
(	NULL
)	NULL
B	NULL
cvs	NULL
B	NULL
aNnFAT1	NULL
ab	NULL
cold	NULL
probe	NULL
»	NULL
#	NULL
®	NULL
#	NULL
&	NULL
win	NULL
wie	NULL
60	NULL
%	NULL
«	NULL
®	NULL
#	NULL
bd	NULL
M34	NULL
``	NULL
I	NULL
200	NULL
150	NULL
100	NULL
.	NULL

Relative	NULL
binding	NULL
activity	NULL
(	NULL
%	NULL
)	NULL
102	NULL
3	NULL
4	NULL
50	NULL
6	NULL
1	NULL
8	NULL
9	NULL
FIGURE	NULL
5	NULL
.	NULL

DNA	NULL
binding	NULL
activity	NULL
of	NULL
NFAT	NULL
following	NULL
CD16	NULL
cross-link	NULL
ing	NULL
was	NULL
suppressed	NULL
by	NULL
thiol	NULL
deprivation	NULL
or	NULL
H	NULL
,	NULL
O	NULL
;	NULL
treatment	NULL
and	NULL
restored	NULL
by	NULL
addition	NULL
of	NULL
thiol	NULL
compounds	NULL
.	NULL

IL-2-preactivated	NULL
NK	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
or	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
medium	NULL
for	NULL
11	NULL
h	NULL
,	NULL
then	NULL
treated	NULL
with	NULL
the	NULL
indicated	NULL
treatments	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
for	NULL
1	NULL
h	NULL
,	NULL
and	NULL
harvested	NULL
for	NULL
EMSA	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
treated	NULL
with	NULL
control	NULL
anti-CD56	NULL
mAb	NULL
in	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
medium	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
treated	NULL
with	NULL
anti-CD16	NULL
mAb	NULL
in	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
medium	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
,	NULL
treated	NULL
with	NULL
anti-CD16	NULL
mAb	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
doses	NULL
of	NULL
H	NULL
,	NULL
O	NULL
;	NULL
in	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
medium	NULL
;	NULL
Zanes	NULL
5-7	NULL
,	NULL
treated	NULL
with	NULL
anti-CD16	NULL
mAb	NULL
in	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
medium	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
2-ME	NULL
or	NULL
NAC	NULL
;	NULL
lane	NULL
8	NULL
,	NULL
anti-NFAT	NULL
Ab	NULL
was	NULL
added	NULL
to	NULL
the	NULL
same	NULL
sample	NULL
as	NULL
lane	NULL
2	NULL
;	NULL
lane	NULL
9	NULL
,	NULL
cold	NULL
probe	NULL
was	NULL
added	NULL
to	NULL
the	NULL
same	NULL
sample	NULL
as	NULL
lane	NULL
2	NULL
.	NULL

The	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Quantitative	NULL
presentation	NULL
(	NULL
percentage	NULL
of	NULL
FasL	NULL
mRNA	NULL
expression	NULL
in	NULL
each	NULL
sample	NULL
compared	NULL
with	NULL
the	NULL
sample	NULL
treated	NULL
with	NULL
anti-CD16	NULL
in	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
medium	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
is	NULL
also	NULL
shown	NULL
using	NULL
data	NULL
obtained	NULL
by	NULL
PhosphorImage	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
)	NULL
analysis	NULL
.	NULL

even	NULL
augmented	NULL
by	NULL
2-ME	NULL
treatment	NULL
compared	NULL
with	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
thiol-reducing	NULL
compounds	NULL
are	NULL
required	NULL
for	NULL
optimal	NULL
activation	NULL
of	NULL
NFAT	NULL
.	NULL

This	NULL
result	NULL
also	NULL
suggests	NULL
that	NULL
oxidative	NULL
stress	NULL
inhibits	NULL
CD16-induced	NULL
FasL	NULL
expression	NULL
at	NULL
the	NULL
level	NULL
of	NULL
,	NULL
or	NULL
upstream	NULL
to	NULL
,	NULL
NFAT	NULL
activation	NULL
.	NULL

Thiol	NULL
deprivation	NULL
and	NULL
addition	NULL
of	NULL
H	NULL
,	NULL
O	NULL
;	NULL
suppressed	NULL
calcineurin	NULL
phosphatase	NULL
activity	NULL
in	NULL
vitro	NULL
Activation	NULL
of	NULL
NFAT	NULL
is	NULL
known	NULL
to	NULL
be	NULL
regulated	NULL
by	NULL
a	NULL
CsA-sensitive	NULL
,	NULL
calcium/calmodulin-dependent	NULL
serine/threonine	NULL
phosphatase	NULL
,	NULL
calcineurin	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
examined	NULL
whether	NULL
oxidative	NULL
stress	NULL
affects	NULL
calcineurin	NULL
activity	NULL
in	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
.	NULL

Culture	NULL
in	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
medium	NULL
for	NULL
12	NULL
h	NULL
markedly	NULL
suppressed	NULL
calcineurin	NULL
activity	NULL
compared	NULL
with	NULL
standard	NULL
medium	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

However	NULL
,	NULL
treatment	NULL
of	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
with	NULL
H	NULL
,	NULL
O	NULL
,	NULL
had	NULL
only	NULL
a	NULL
marginal	NULL
effect	NULL
on	NULL
calcineurin	NULL
activity	NULL
,	NULL
even	NULL
with	NULL
1	NULL
mM	NULL
H	NULL
;	NULL
,	NULL
O	NULL
;	NULL
,	NULL
.	NULL

Because	NULL
the	NULL
calcineurin	NULL
assay	NULL
reaction	NULL
mixture	NULL
contained	NULL
DTT	NULL
,	NULL
we	NULL
next	NULL
investigated	NULL
the	NULL
effect	NULL
of	NULL
incubation	NULL
with	NULL
H	NULL
,	NULL
O	NULL
,	NULL
in	NULL
vitro	NULL
of	NULL
lysates	NULL
from	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
,	NULL
which	NULL
had	NULL
not	NULL
been	NULL
treated	NULL
with	NULL
H	NULL
,	NULL
O	NULL
,	NULL
as	NULL
a	NULL
more	NULL
sensitive	NULL
means	NULL
to	NULL
assess	NULL
changes	NULL
in	NULL
calcineurin	NULL
activity	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
calcineurin	NULL
activity	NULL
in	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
was	NULL
inhibited	NULL
by	NULL
H	NULL
,	NULL
O	NULL
,	NULL
in	NULL
a	NULL
dose-dependent	NULL
fashion	NULL
.	NULL

These	NULL
results	NULL
demonstrated	NULL
that	NULL
oxidative	NULL
stress	NULL
,	NULL
including	NULL
thiol	NULL
deprivation	NULL
or	NULL
treatment	NULL
with	NULL
H	NULL
,	NULL
O	NULL
,	NULL
suppressed	NULL
calcineurin	NULL
activity	NULL
in	NULL
NK	NULL
cells	NULL
in	NULL
vitro	NULL
,	NULL
and	NULL
thereby	NULL
suggests	NULL
that	NULL
suppression	NULL
of	NULL
calcineurin	NULL
activity	NULL
is	NULL
a	NULL
mechanism	NULL
by	NULL
which	NULL
oxidative	NULL
stress	NULL
inhibits	NULL
NFAT	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
1992	NULL
>	NULL
>	NULL
in	NULL
otein	NULL
)	NULL
es	NULL
o	NULL
--	NULL
-	NULL
Calcineurin	NULL
activity	NULL
(	NULL
pmol/min	NULL
per	NULL
mg	NULL
of	NULL
pr	NULL
CYS	NULL
+	NULL
-	NULL
+o	NULL
+	NULL
+	NULL
CsA	NULL
_	NULL
-	NULL
-	NULL
-	NULL
-	NULL
+	NULL
Mame	NULL
to	NULL
to	NULL
3	NULL
Lo	NULL
B	NULL
is	NULL
50	NULL
Calcineurin	NULL
activity	NULL
(	NULL
pmol/min	NULL
per	NULL
mg	NULL
of	NULL
protein	NULL
)	NULL
&	NULL
0	NULL
0.01	NULL
0.1	NULL
1	NULL
CsA	NULL
H2O2	NULL
(	NULL
mM	NULL
)	NULL
FIGURE	NULL
6	NULL
.	NULL

Effects	NULL
of	NULL
oxidative	NULL
stress	NULL
,	NULL
including	NULL
thiol	NULL
deprivation	NULL
or	NULL
H	NULL
,	NULL
O	NULL
,	NULL
treatment	NULL
,	NULL
on	NULL
calcineurin	NULL
activity	NULL
.	NULL

A	NULL
,	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
CYS	NULL
(	NULL
+	NULL
)	NULL
or	NULL
CYS	NULL
(	NULL
-	NULL
)	NULL
medium	NULL
for	NULL
11	NULL
h	NULL
,	NULL
then	NULL
treated	NULL
with	NULL
H	NULL
,	NULL
O	NULL
,	NULL
(	NULL
0.1-1	NULL
mM	NULL
)	NULL
or	NULL
CsA	NULL
(	NULL
10	NULL
wM	NULL
)	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
1	NULL
h	NULL
,	NULL
and	NULL
harvested	NULL
for	NULL
calcineurin	NULL
assay	NULL
.	NULL

Means	NULL
+	NULL
SD	NULL
among	NULL
the	NULL
data	NULL
from	NULL
three	NULL
different	NULL
donors	NULL
were	NULL
shown	NULL
.	NULL

The	NULL
data	NULL
indicated	NULL
that	NULL
thiol	NULL
deprivation	NULL
suppressed	NULL
calcineurin	NULL
activity	NULL
in	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
.	NULL

B	NULL
,	NULL
The	NULL
indicated	NULL
concentrations	NULL
of	NULL
H	NULL
,	NULL
O	NULL
,	NULL
or	NULL
10	NULL
uM	NULL
CsA	NULL
were	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
mixtures	NULL
with	NULL
lysates	NULL
from	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
,	NULL
and	NULL
calcineurin	NULL
activity	NULL
was	NULL
assayed	NULL
.	NULL

A	NULL
representative	NULL
of	NULL
three	NULL
repeated	NULL
experiments	NULL
is	NULL
presented	NULL
.	NULL

The	NULL
results	NULL
demonstrate	NULL
that	NULL
calcineurin	NULL
activity	NULL
in	NULL
lysates	NULL
from	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
was	NULL
inhibited	NULL
by	NULL
addition	NULL
of	NULL
H	NULL
,	NULL
O	NULL
,	NULL
in	NULL
vitro	NULL
.	NULL

activation	NULL
and	NULL
FasL	NULL
induction	NULL
following	NULL
CD16	NULL
ligation	NULL
on	NULL
NK	NULL
cells	NULL
.	NULL

Discussion	NULL
The	NULL
present	NULL
study	NULL
demonstrated	NULL
that	NULL
FasL	NULL
expression	NULL
following	NULL
CD16	NULL
ligation	NULL
on	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
was	NULL
suppressed	NULL
by	NULL
thiol	NULL
deprivation	NULL
and	NULL
restored	NULL
by	NULL
addition	NULL
of	NULL
thiol	NULL
compounds	NULL
,	NULL
suggesting	NULL
that	NULL
cellular	NULL
reducing	NULL
status	NULL
is	NULL
required	NULL
for	NULL
FasL	NULL
induction	NULL
in	NULL
CD16-stimulated	NULL
NK	NULL
cells	NULL
.	NULL

This	NULL
notion	NULL
was	NULL
further	NULL
supported	NULL
by	NULL
the	NULL
findings	NULL
that	NULL
another	NULL
oxidative	NULL
stressor	NULL
,	NULL
H	NULL
,	NULL
O	NULL
,	NULL
also	NULL
inhibited	NULL
CD16-induced	NULL
FasL	NULL
expression	NULL
and	NULL
that	NULL
intracellular	NULL
ROS	NULL
levels	NULL
were	NULL
decreased	NULL
following	NULL
treatment	NULL
with	NULL
anti-CD16	NULL
mAb	NULL
.	NULL

We	NULL
further	NULL
showed	NULL
that	NULL
oxidative	NULL
stress	NULL
,	NULL
including	NULL
thiol	NULL
deprivation	NULL
or	NULL
H	NULL
,	NULL
O	NULL
,	NULL
treatment	NULL
,	NULL
suppressed	NULL
events	NULL
upstream	NULL
of	NULL
FasL	NULL
expression	NULL
,	NULL
namely	NULL
calcineurin	NULL
and	NULL
NFAT	NULL
activation	NULL
,	NULL
suggesting	NULL
that	NULL
oxidative	NULL
stress	NULL
suppressed	NULL
CD16-induced	NULL
FasL	NULL
expression	NULL
through	NULL
inhibition	NULL
of	NULL
calcineurin/NFAT	NULL
activation	NULL
or	NULL
event	NULL
(	NULL
s	NULL
)	NULL
upstream	NULL
thereof	NULL
.	NULL

The	NULL
regulation	NULL
of	NULL
a	NULL
number	NULL
of	NULL
transcriptional	NULL
factors	NULL
by	NULL
cellular	NULL
redox	NULL
status	NULL
is	NULL
well	NULL
described	NULL
(	NULL
14	NULL
)	NULL
.	NULL

However	NULL
,	NULL
this	NULL
regulation	NULL
is	NULL
quite	NULL
complicated	NULL
.	NULL

Although	NULL
H	NULL
,	NULL
O	NULL
,	NULL
is	NULL
known	NULL
to	NULL
be	NULL
a	NULL
potent	NULL
activator	NULL
of	NULL
NF-KB	NULL
(	NULL
29	NULL
)	NULL
,	NULL
and	NULL
reductants	NULL
generally	NULL
decrease	NULL
transcriptional	NULL
activity	NULL
of	NULL
p53	NULL
(	NULL
14	NULL
)	NULL
,	NULL
thiol-reducing	NULL
compounds	NULL
activate	NULL
AP-1	NULL
(	NULL
30	NULL
,	NULL
31	NULL
)	NULL
and	NULL
even	NULL
increase	NULL
DNA-binding	NULL
activity	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
REDOX	NULL
CONTROL	NULL
OF	NULL
Fas	NULL
LIGAND	NULL
EXPRESSION	NULL
IN	NULL
HUMAN	NULL
NK	NULL
CELLS	NULL
(	NULL
32	NULL
)	NULL
.	NULL

In	NULL
terms	NULL
of	NULL
NFAT	NULL
,	NULL
sublethal	NULL
levels	NULL
of	NULL
oxidative	NULL
stress	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
suppress	NULL
its	NULL
transcriptional	NULL
activity	NULL
and	NULL
,	NULL
thereby	NULL
,	NULL
IL-2	NULL
mRNA	NULL
expression	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
33	NULL
)	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
found	NULL
that	NULL
DNA-binding	NULL
activity	NULL
of	NULL
NFAT	NULL
is	NULL
modulated	NULL
by	NULL
nitric	NULL
oxide	NULL
,	NULL
which	NULL
is	NULL
highly	NULL
reactive	NULL
with	NULL
superoxide	NULL
anion	NULL
and	NULL
thiols	NULL
(	NULL
Furuke	NULL
et	NULL
al	NULL
.	NULL

,	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

In	NULL
the	NULL
current	NULL
study	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
DNA-binding	NULL
activity	NULL
of	NULL
NFAT	NULL
is	NULL
suppressed	NULL
by	NULL
oxidative	NULL
stress	NULL
,	NULL
such	NULL
as	NULL
thiol	NULL
deficiency	NULL
or	NULL
treatment	NULL
with	NULL
H	NULL
,	NULL
O	NULL
,	NULL
and	NULL
thiol-reducing	NULL
compounds	NULL
reversed	NULL
it	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
thiol-mediated	NULL
reducing	NULL
condition	NULL
is	NULL
required	NULL
for	NULL
NFAT	NULL
activation	NULL
in	NULL
CD16-activated	NULL
NK	NULL
cells	NULL
.	NULL

Activation	NULL
of	NULL
NFAT	NULL
is	NULL
well	NULL
known	NULL
to	NULL
be	NULL
regulated	NULL
by	NULL
a	NULL
serine/	NULL
threonine	NULL
phosphatase	NULL
,	NULL
calcineurin	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Since	NULL
superoxide	NULL
dismutase	NULL
protects	NULL
calcineurin	NULL
from	NULL
inactivation	NULL
(	NULL
34	NULL
)	NULL
and	NULL
a	NULL
thiol	NULL
reducing	NULL
enzyme	NULL
,	NULL
thioredoxin	NULL
,	NULL
inhibits	NULL
activity	NULL
of	NULL
CsA	NULL
and	NULL
FK506	NULL
,	NULL
inhibitors	NULL
for	NULL
calcineurin	NULL
(	NULL
35	NULL
)	NULL
,	NULL
we	NULL
hypothesized	NULL
that	NULL
cellular	NULL
redox	NULL
status	NULL
affects	NULL
calcineurin	NULL
activity	NULL
,	NULL
resulting	NULL
in	NULL
regulation	NULL
of	NULL
NFAT	NULL
activity	NULL
.	NULL

The	NULL
evidence	NULL
that	NULL
the	NULL
active	NULL
site	NULL
of	NULL
calcineurin	NULL
contains	NULL
Fe	NULL
and	NULL
Zn	NULL
ions	NULL
(	NULL
36	NULL
)	NULL
,	NULL
both	NULL
of	NULL
which	NULL
are	NULL
redox-sensitive	NULL
,	NULL
supports	NULL
this	NULL
possibility	NULL
.	NULL

Our	NULL
study	NULL
demonstrated	NULL
that	NULL
lysates	NULL
from	NULL
thiol-de-pleted	NULL
NK	NULL
cells	NULL
contained	NULL
lower	NULL
calcineurin	NULL
activity	NULL
than	NULL
those	NULL
from	NULL
normal	NULL
NK	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
calcineurin	NULL
activity	NULL
also	NULL
requires	NULL
thiol-mediated	NULL
reducing	NULL
conditions	NULL
.	NULL

However	NULL
,	NULL
calcineurin	NULL
activity	NULL
in	NULL
lysates	NULL
from	NULL
H	NULL
,	NULL
O	NULL
,	NULL
-treated	NULL
NK	NULL
cells	NULL
was	NULL
not	NULL
significantly	NULL
altered	NULL
.	NULL

We	NULL
also	NULL
demonstrated	NULL
that	NULL
thiol	NULL
deprivation	NULL
was	NULL
more	NULL
potent	NULL
for	NULL
increasing	NULL
intracellular	NULL
peroxide	NULL
levels	NULL
than	NULL
H	NULL
,	NULL
O	NULL
,	NULL
treatment	NULL
.	NULL

In	NULL
the	NULL
calcineurin	NULL
assay	NULL
,	NULL
sufficient	NULL
doses	NULL
of	NULL
a	NULL
reducing	NULL
reagent	NULL
,	NULL
DTT	NULL
(	NULL
0.5	NULL
mM	NULL
)	NULL
,	NULL
were	NULL
required	NULL
to	NULL
measure	NULL
calcineurin	NULL
activity	NULL
in	NULL
vitro	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
DTT	NULL
reversed	NULL
an	NULL
H	NULL
,	NULL
O	NULL
,	NULL
effect	NULL
on	NULL
calcineurin	NULL
activity	NULL
during	NULL
the	NULL
assay	NULL
,	NULL
although	NULL
it	NULL
was	NULL
not	NULL
sufficient	NULL
to	NULL
reverse	NULL
the	NULL
effect	NULL
in	NULL
cells	NULL
cultured	NULL
under	NULL
conditions	NULL
of	NULL
thiol	NULL
deprivation	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
H	NULL
;	NULL
O	NULL
;	NULL
,	NULL
treatment	NULL
can	NULL
indeed	NULL
inhibit	NULL
calcineurin	NULL
activity	NULL
,	NULL
we	NULL
performed	NULL
an	NULL
experiment	NULL
in	NULL
which	NULL
H	NULL
,	NULL
O	NULL
,	NULL
was	NULL
directly	NULL
added	NULL
into	NULL
the	NULL
reaction	NULL
mixture	NULL
with	NULL
the	NULL
lysate	NULL
from	NULL
IL-2-preactivated	NULL
NK	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
result	NULL
showed	NULL
that	NULL
H	NULL
,	NULL
O	NULL
,	NULL
inhibited	NULL
calcineurin	NULL
activity	NULL
in	NULL
the	NULL
lysate	NULL
in	NULL
a	NULL
dose-dependent	NULL
fashion	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
findings	NULL
suggest	NULL
that	NULL
oxidative	NULL
stress	NULL
,	NULL
including	NULL
thiol	NULL
deprivation	NULL
or	NULL
H	NULL
,	NULL
O	NULL
,	NULL
treatment	NULL
,	NULL
inhibits	NULL
FasL	NULL
expression	NULL
induced	NULL
in	NULL
activated	NULL
NK	NULL
cells	NULL
through	NULL
suppression	NULL
of	NULL
activation	NULL
of	NULL
calcineurin-NFAT	NULL
pathway	NULL
.	NULL

However	NULL
,	NULL
thiol	NULL
deprivation	NULL
appears	NULL
to	NULL
induce	NULL
oxidative	NULL
stress	NULL
more	NULL
efficiently	NULL
than	NULL
addition	NULL
of	NULL
H	NULL
,	NULL
O	NULL
,	NULL
since	NULL
reduced	NULL
calcineurin	NULL
activity	NULL
following	NULL
thiol	NULL
deprivation	NULL
was	NULL
observed	NULL
even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
DTT	NULL
in	NULL
the	NULL
reaction	NULL
.	NULL

Recent	NULL
studies	NULL
on	NULL
Fas/FasL	NULL
interaction	NULL
have	NULL
revealed	NULL
that	NULL
FasL-induced	NULL
apoptosis	NULL
is	NULL
involved	NULL
in	NULL
a	NULL
number	NULL
of	NULL
pathological	NULL
condi-tions	NULL
,	NULL
including	NULL
eliminating	NULL
virus-infected	NULL
or	NULL
malignant	NULL
cells	NULL
,	NULL
tumor	NULL
tolerance	NULL
from	NULL
cytotoxic	NULL
lymphocytes	NULL
,	NULL
graft	NULL
rejection	NULL
,	NULL
acute	NULL
hepatitis	NULL
,	NULL
and	NULL
autoimmune	NULL
disease	NULL
(	NULL
1	NULL
,	NULL
2	NULL
,	NULL
37-39	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
since	NULL
ROS	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
pathophysiology	NULL
of	NULL
these	NULL
disorders	NULL
(	NULL
40	NULL
)	NULL
,	NULL
oxidative	NULL
stress	NULL
appears	NULL
to	NULL
colocalize	NULL
with	NULL
sites	NULL
of	NULL
Fas/	NULL
FasL	NULL
interaction	NULL
.	NULL

Although	NULL
there	NULL
have	NULL
been	NULL
several	NULL
reports	NULL
on	NULL
the	NULL
redox	NULL
regulation	NULL
in	NULL
Fas	NULL
receptor	NULL
expression	NULL
(	NULL
41	NULL
,	NULL
42	NULL
)	NULL
and	NULL
on	NULL
the	NULL
involvement	NULL
of	NULL
ROS	NULL
in	NULL
FasL-induction	NULL
in	NULL
T	NULL
cells	NULL
activated	NULL
through	NULL
TCR-stimulation	NULL
(	NULL
43	NULL
,	NULL
44	NULL
)	NULL
,	NULL
this	NULL
is	NULL
the	NULL
first	NULL
study	NULL
showing	NULL
the	NULL
redox	NULL
control	NULL
of	NULL
FasL	NULL
expression	NULL
in	NULL
NK	NULL
cell	NULL
activation	NULL
and	NULL
exploring	NULL
the	NULL
mechanism	NULL
of	NULL
that	NULL
control	NULL
.	NULL

Our	NULL
results	NULL
may	NULL
provide	NULL
not	NULL
only	NULL
means	NULL
to	NULL
maintain	NULL
optimal	NULL
NK	NULL
functions	NULL
but	NULL
also	NULL
possible	NULL
therapeutics	NULL
for	NULL
such	NULL
pathological	NULL
conditions	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Dr.	NULL
C.	NULL
Wilson	NULL
for	NULL
critical	NULL
review	NULL
of	NULL
the	NULL
manuscript	NULL
and	NULL
Dr.	NULL
K.	NULL
Ishii	NULL
for	NULL
performing	NULL
some	NULL
of	NULL
the	NULL
flow	NULL
cytometric	NULL
analyses	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
References	NULL
1.	NULL
wo	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

Lynch	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
F.	NULL
Ramsdell	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Alderson	NULL
.	NULL

1995	NULL
.	NULL

Fas	NULL
and	NULL
FasL	NULL
in	NULL
the	NULL
homeostatic	NULL
regulation	NULL
of	NULL
immune	NULL
responses	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
16:569.	NULL
.	NULL

Nagata	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
P.	NULL
Golstein	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
Fas	NULL
death	NULL
factor	NULL
.	NULL

Science	NULL
267:1449.	NULL
.	NULL

Dhein	NULL
,	NULL
J.	NULL
,	NULL
H.	NULL
Walczak	NULL
,	NULL
C.	NULL
Biumier	NULL
,	NULL
K.-M.	NULL
Debatin	NULL
,	NULL
and	NULL
P.	NULL
H.	NULL
Krammer	NULL
.	NULL

1995	NULL
.	NULL

Autocrine	NULL
T-cell	NULL
suicide	NULL
mediated	NULL
by	NULL
APO-1/	NULL
(	NULL
Pas/CD95	NULL
)	NULL
.	NULL

Nature	NULL
373:438.	NULL
.	NULL

Brunner	NULL
,	NULL
T.	NULL
,	NULL
R.	NULL
J.	NULL
Mogil	NULL
,	NULL
D.	NULL
LaFace	NULL
,	NULL
N.	NULL
J.	NULL
Yoo	NULL
,	NULL
A.	NULL
Mahboubi	NULL
,	NULL
F.	NULL
Echeverri	NULL
,	NULL
S.	NULL
J.	NULL
Martin	NULL
,	NULL
W.	NULL
R.	NULL
Force	NULL
,	NULL
D.	NULL
H.	NULL
Lynchi	NULL
,	NULL
C.	NULL
F.	NULL
Ware	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
Green	NULL
.	NULL

1995	NULL
.	NULL

Cell-autonomous	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
/Fas-ligand	NULL
interaction	NULL
mediates	NULL
activation-induced	NULL
apoptosis	NULL
in	NULL
T-cell	NULL
hybridomas	NULL
.	NULL

Nature	NULL
373:441.	NULL
.	NULL

Ju	NULL
,	NULL
S-T.	NULL
,	NULL
D.	NULL
J.	NULL
Panka	NULL
,	NULL
H.	NULL
Cui	NULL
,	NULL
R.	NULL
Eitinger	NULL
,	NULL
M.	NULL
El-Khatib	NULL
,	NULL
D.	NULL
H.	NULL
Sher	NULL
,	NULL
B	NULL
.	NULL

Z.	NULL
Stanger	NULL
,	NULL
and	NULL
A.	NULL
Marshak-Rothstein	NULL
.	NULL

1995	NULL
.	NULL

Fas	NULL
(	NULL
CD95	NULL
)	NULL
/FasL	NULL
interactions	NULL
required	NULL
for	NULL
programmed	NULL
cell	NULL
death	NULL
after	NULL
T-cell	NULL
activation	NULL
.	NULL

Nature	NULL
373:444.	NULL
.	NULL

Eischen	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
J.	NULL
D.	NULL
Schilling	NULL
,	NULL
D.	NULL
H.	NULL
Lynch	NULL
,	NULL
P.	NULL
H.	NULL
Krammer	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Leibson	NULL
.	NULL

1996	NULL
.	NULL

Fc	NULL
receptor-induced	NULL
expression	NULL
of	NULL
Fas	NULL
ligand	NULL
on	NULL
activated	NULL
NK	NULL
cells	NULL
facilitates	NULL
cell-mediated	NULL
cytotoxicity	NULL
and	NULL
subsequent	NULL
autocrine	NULL
NK	NULL
cell	NULL
apoptosis	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

156:2693.	NULL
.	NULL

Eischen	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
B.	NULL
L.	NULL
Williams	NULL
,	NULL
W.	NULL
Zhang	NULL
,	NULL
L.	NULL
E.	NULL
Samelson	NULL
,	NULL
D.	NULL
H.	NULL
Lynch	NULL
,	NULL
R.	NULL
T.	NULL
Abraham	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Leibson	NULL
.	NULL

1997	NULL
.	NULL

ZAP-70	NULL
tyrosine	NULL
kinase	NULL
is	NULL
required	NULL
for	NULL
the	NULL
up-regulation	NULL
of	NULL
Fas	NULL
ligand	NULL
in	NULL
activation-induced	NULL
T	NULL
cell	NULL
apoptosis	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

159:1135.	NULL
.	NULL

Latinis	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
L.	NULL
L.	NULL
Carr	NULL
,	NULL
E.	NULL
J.	NULL
Peterson	NULL
,	NULL
L.	NULL
A.	NULL
Norian	NULL
,	NULL
S.	NULL
L.	NULL
Eliason	NULL
,	NULL
and	NULL
G.	NULL
A.	NULL
Koretsky	NULL
.	NULL

1997	NULL
.	NULL

Regulation	NULL
of	NULL
CD95	NULL
(	NULL
Fas	NULL
)	NULL
ligand	NULL
expression	NULL
by	NULL
TCR-mediated	NULL
signaling	NULL
events	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:4602.	NULL
.	NULL

Brunner	NULL
,	NULL
T.	NULL
,	NULL
N.	NULL
J.	NULL
Yoo	NULL
,	NULL
D.	NULL
LaFace	NULL
,	NULL
C.	NULL
F.	NULL
Ware	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
Green	NULL
.	NULL

1996	NULL
.	NULL

Activa-	NULL
tion-induced	NULL
cell	NULL
death	NULL
in	NULL
murine	NULL
T	NULL
cell	NULL
hybridomas	NULL
.	NULL

Differential	NULL
regulation	NULL
of	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
versus	NULL
Fas	NULL
ligand	NULL
expression	NULL
by	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

8	NULL
:	NULL
1017	NULL
.	NULL

Yang	NULL
,	NULL
Y.	NULL
,	NULL
S.	NULL
Minucci	NULL
,	NULL
K.	NULL
Ozato	NULL
,	NULL
R.	NULL
A.	NULL
Heyman	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Ashwell	NULL
.	NULL

1995	NULL
.	NULL

Efficient	NULL
inhibition	NULL
of	NULL
activation-induced	NULL
Fas	NULL
ligand	NULL
up-regulation	NULL
and	NULL
T	NULL
cell	NULL
apoptosis	NULL
by	NULL
retinoids	NULL
requires	NULL
occupancy	NULL
of	NULL
both	NULL
retinoid	NULL
X	NULL
receptors	NULL
and	NULL
retinoic	NULL
acid	NULL
re-ceptors	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:18672	NULL
.	NULL

Latinis	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
L.	NULL
A.	NULL
Norian	NULL
,	NULL
S.	NULL
L.	NULL
Eliason	NULL
,	NULL
and	NULL
G.	NULL
A.	NULL
Koretzky	NULL
.	NULL

1997	NULL
.	NULL

Two	NULL
NFAT	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
participate	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
CD95	NULL
(	NULL
Fas	NULL
)	NULL
ligand	NULL
expression	NULL
in	NULL
activated	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:31427	NULL
.	NULL

Matsui	NULL
,	NULL
K.	NULL
,	NULL
S.	NULL
Omura	NULL
,	NULL
H.	NULL
Cui	NULL
,	NULL
S.	NULL
L.	NULL
Schauer	NULL
,	NULL
G.	NULL
E.	NULL
Sonenshein	NULL
,	NULL
and	NULL
S.-T.	NULL
Ju	NULL
.	NULL

1997	NULL
.	NULL

Proteasome	NULL
regulation	NULL
of	NULL
Fas	NULL
ligand	NULL
cytotoxicity	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

27	NULL
:	NULL
2269	NULL
.	NULL

Monteiro	NULL
,	NULL
H.	NULL
P.	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Stem	NULL
.	NULL

1996	NULL
.	NULL

Redox	NULL
modulation	NULL
of	NULL
tyrosine	NULL
phosphory-lation-dependent	NULL
signal	NULL
transduction	NULL
pathways	NULL
.	NULL

Free	NULL
Radical	NULL
Biol	NULL
.	NULL

Med	NULL
.	NULL

21:323	NULL
.	NULL

Sun	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
L.	NULL
W.	NULL
Oberley	NULL
.	NULL

1996	NULL
.	NULL

Redox	NULL
regulation	NULL
of	NULL
transcriptional	NULL
activators	NULL
.	NULL

Free	NULL
Radical	NULL
Biol	NULL
.	NULL

Med	NULL
.	NULL

21:335	NULL
.	NULL

Yamauchi	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
E.	NULL
T.	NULL
Bloom	NULL
.	NULL

1993	NULL
.	NULL

Requirement	NULL
of	NULL
thiol	NULL
compounds	NULL
as	NULL
reducing	NULL
agents	NULL
for	NULL
IL-2-mediated	NULL
induction	NULL
of	NULL
LAK	NULL
activity	NULL
and	NULL
proliferation	NULL
of	NULL
human	NULL
NK	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

151:5535	NULL
.	NULL

Yamauchi	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
E.	NULL
T.	NULL
Bloom	NULL
.	NULL

1997	NULL
.	NULL

Control	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
human	NULL
natural	NULL
killer	NULL
cells	NULL
through	NULL
redox	NULL
regulation	NULL
of	NULL
expression	NULL
and	NULL
phosphorylation	NULL
of	NULL
retinoblastoma	NULL
gene	NULL
product	NULL
protein	NULL
.	NULL

Blood	NULL
89:4092	NULL
.	NULL

Furuke	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
E.	NULL
T.	NULL
Bloom	NULL
.	NULL

1998	NULL
.	NULL

Redox-sensitive	NULL
events	NULL
in	NULL
Fas-induced	NULL
apoptosis	NULL
in	NULL
human	NULL
natural	NULL
killer	NULL
cells	NULL
include	NULL
ceramide	NULL
generation	NULL
and	NULL
protein	NULL
tyrosine	NULL
dephosphorylation	NULL
.	NULL

Inf	NULL
.	NULL

Immunol	NULL
.	NULL

10:1261	NULL
.	NULL

Kayagaki	NULL
,	NULL
N.	NULL
,	NULL
A.	NULL
Kawasaki	NULL
,	NULL
T.	NULL
Ebata	NULL
,	NULL
H.	NULL
Obhmoto	NULL
,	NULL
S.	NULL
Ikeda	NULL
,	NULL
S.	NULL
Inoue	NULL
,	NULL
K.	NULL
Yoshino	NULL
,	NULL
K.	NULL
Okumura	NULL
,	NULL
and	NULL
H.	NULL
Yagita	NULL
.	NULL

1995	NULL
.	NULL

Metalloproteinase-mediated	NULL
release	NULL
of	NULL
human	NULL
Fas	NULL
ligand	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182:1777	NULL
.	NULL

Furuke	NULL
,	NULL
K.	NULL
,	NULL
T.	NULL
Sasada	NULL
,	NULL
Y.	NULL
Ueda-Taniguchi	NULL
,	NULL
A.	NULL
Yamauchi	NULL
,	NULL
T.	NULL
Inamoto	NULL
,	NULL
Y.	NULL
Yamaoka	NULL
,	NULL
H.	NULL
Masutani	NULL
,	NULL
and	NULL
J.	NULL
Yodoi	NULL
.	NULL

1997	NULL
.	NULL

Role	NULL
of	NULL
intracellular	NULL
redox	NULL
status	NULL
in	NULL
apoptosis	NULL
induction	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
lymphocytes	NULL
by	NULL
13-cis-retinoic	NULL
acid	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

57:4916	NULL
.	NULL

Burd	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
W.	NULL
C.	NULL
Thompson	NULL
,	NULL
E.	NULL
E.	NULL
Max	NULL
,	NULL
and	NULL
F.	NULL
C.	NULL
Mills	NULL
.	NULL

1995	NULL
.	NULL

Activated	NULL
mast	NULL
cells	NULL
secrete	NULL
interleukin-13	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181:1373	NULL
.	NULL

Schreiber	NULL
,	NULL
E.	NULL
,	NULL
P.	NULL
Matthias	NULL
,	NULL
M.	NULL
M.	NULL
Miiller	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
.	NULL

1989	NULL
.	NULL

Rapid	NULL
detection	NULL
of	NULL
octamer	NULL
binding	NULL
proteins	NULL
with	NULL
``	NULL
mini-extracts	NULL
,	NULL
``	NULL
prepared	NULL
from	NULL
a	NULL
small	NULL
number	NULL
of	NULL
cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17:6419	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

1993	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
Z	NULL
.	NULL

Miner	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1993	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
pre-existing	NULL
and	NULL
nuclear	NULL
forms	NULL
of	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

151:837	NULL
.	NULL

Aramburu	NULL
,	NULL
J.	NULL
,	NULL
L.	NULL
Azzoni	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
and	NULL
B.	NULL
Perussia	NULL
.	NULL

1995	NULL
.	NULL

Activation	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
nuclear	NULL
factors	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
NFATp	NULL
and	NULL
NFATc	NULL
,	NULL
in	NULL
human	NULL
natural	NULL
killer	NULL
cells	NULL
:	NULL
regulation	NULL
upon	NULL
CD16	NULL
ligand	NULL
binding	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182:801	NULL
.	NULL

Fruman	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
C.	NULL
B.	NULL
Klee	NULL
,	NULL
B.	NULL
E.	NULL
Bieter	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Burakoff	NULL
.	NULL

1992	NULL
.	NULL

Calcineurin	NULL
phosphatase	NULL
activity	NULL
in	NULL
T	NULL
lymphocytes	NULL
is	NULL
inhibited	NULL
by	NULL
FK506	NULL
and	NULL
cyclosporin	NULL
A.	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:3686	NULL
.	NULL

Burow	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
G.	NULL
Valet	NULL
.	NULL

1987	NULL
.	NULL

Flow-cytometric	NULL
characterization	NULL
of	NULL
stimulation	NULL
,	NULL
free	NULL
radical	NULL
formation	NULL
,	NULL
peroxidase	NULL
activity	NULL
and	NULL
phagocytosis	NULL
of	NULL
human	NULL
granulo-cytes	NULL
with	NULL
2,7-dichlorofluorescein	NULL
(	NULL
DCF	NULL
)	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

43:128	NULL
.	NULL

Lahdenpohja	NULL
,	NULL
N.	NULL
,	NULL
K.	NULL
Savinainen	NULL
,	NULL
and	NULL
M.	NULL
Hurme	NULL
.	NULL

1998	NULL
.	NULL

Pre-exposure	NULL
to	NULL
oxidative	NULL
stress	NULL
decreases	NULL
the	NULL
nuclear	NULL
factor-	NULL
«	NULL
B-dependent	NULL
transcription	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

160:1354	NULL
.	NULL

Holtz-Heppelmann	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
A.	NULL
Algeciras	NULL
,	NULL
A.	NULL
D.	NULL
Badley	NULL
,	NULL
and	NULL
C.	NULL
V.	NULL
Paya	NULL
.	NULL

1998	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
FasL	NULL
promoter-enhancer	NULL
region	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273:4416	NULL
.	NULL

Schreiber	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabiree	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
13:136	NULL
.	NULL

Schreck	NULL
,	NULL
R.	NULL
,	NULL
P.	NULL
Ricber	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Bacuerle	NULL
.	NULL

1991	NULL
.	NULL

Reactive	NULL
oxygen	NULL
intermediates	NULL
as	NULL
apparently	NULL
widely	NULL
used	NULL
messengers	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
NF-KB	NULL
transcription	NULL
factor	NULL
and	NULL
HIV-1	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10:2247	NULL
.	NULL

Abate	NULL
,	NULL
C.	NULL
,	NULL
L.	NULL
Patel	NULL
,	NULL
F.	NULL
J.	NULL
Rauscher	NULL
I	NULL
,	NULL
and	NULL
T.	NULL
Curran	NULL
.	NULL

1990	NULL
.	NULL

Redox	NULL
regulation	NULL
of	NULL
Fos	NULL
and	NULL
Jun	NULL
DNA	NULL
binding	NULL
activity	NULL
in	NULL
vitro	NULL
.	NULL

Science	NULL
249:1157	NULL
.	NULL

Galter	NULL
,	NULL
D.	NULL
S.	NULL
,	NULL
S.	NULL
Mihm	NULL
,	NULL
and	NULL
W.	NULL
Drige	NULL
.	NULL

1994	NULL
.	NULL

Distinct	NULL
effects	NULL
of	NULL
glutathione	NULL
disulphide	NULL
on	NULL
the	NULL
nuclear	NULL
transcription	NULL
factors	NULL
«	NULL
B	NULL
and	NULL
the	NULL
activator	NULL
protein-1	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

221:639	NULL
.	NULL

Hayashi	NULL
,	NULL
T.	NULL
,	NULL
Y.	NULL
Ueno	NULL
,	NULL
and	NULL
T.	NULL
Okamoto	NULL
.	NULL

1993	NULL
.	NULL

Oxidoreductive	NULL
regulation	NULL
of	NULL
nuclear	NULL
factor	NULL
xB	NULL
.	NULL

Involvement	NULL
of	NULL
a	NULL
cellular	NULL
reducing	NULL
catalyst	NULL
thioredoxin	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:11380	NULL
.	NULL

Beiging	NULL
,	NULL
L.	NULL
,	NULL
M.	NULL
Chen	NULL
,	NULL
and	NULL
R.	NULL
L.	NULL
Whisler	NULL
.	NULL

1996	NULL
.	NULL

Sublethal	NULL
levels	NULL
of	NULL
oxidative	NULL
stress	NULL
stimulate	NULL
transcriptional	NULL
activation	NULL
of	NULL
c-jun	NULL
and	NULL
suppress	NULL
IL-2	NULL
promoter	NULL
activation	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

157:160	NULL
.	NULL

Wang	NULL
,	NULL
X.	NULL
,	NULL
V.	NULL
C.	NULL
Culotta	NULL
,	NULL
and	NULL
C.	NULL
B.	NULL
Klee	NULL
.	NULL

1996	NULL
.	NULL

Superoxide	NULL
dismutase	NULL
protects	NULL
calcineurin	NULL
from	NULL
inactivation	NULL
.	NULL

Nature	NULL
383:434	NULL
.	NULL

Furuke	NULL
,	NULL
K.	NULL
,	NULL
H.	NULL
Nakamura	NULL
,	NULL
T.	NULL
Hori	NULL
,	NULL
S.	NULL
Iwata	NULL
,	NULL
N.	NULL
Mackawa	NULL
,	NULL
T.	NULL
Inamoto	NULL
,	NULL
Y.	NULL
Yamaoka	NULL
,	NULL
and	NULL
J.	NULL
Yodoi	NULL
.	NULL

1995	NULL
.	NULL

Suppression	NULL
of	NULL
adult	NULL
T	NULL
cell	NULL
leukemia-derived	NULL
factor/human	NULL
thioredoxin	NULL
induction	NULL
by	NULL
FK506	NULL
and	NULL
cyclosporin	NULL
A	NULL
:	NULL
a	NULL
new	NULL
mechanism	NULL
of	NULL
immune	NULL
modulation	NULL
via	NULL
redox	NULL
control	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

7:985	NULL
.	NULL

Kissinger	NULL
,	NULL
C.	NULL
R.	NULL
,	NULL
H.	NULL
E.	NULL
Parge	NULL
,	NULL
D.	NULL
R.	NULL
Knighton	NULL
,	NULL
C.	NULL
T.	NULL
Lewis	NULL
,	NULL
L.	NULL
A.	NULL
Pelletier	NULL
,	NULL
A.	NULL
Tempoezyk	NULL
,	NULL
V.	NULL
J.	NULL
Kalish	NULL
,	NULL
K.	NULL
D.	NULL
Tucker	NULL
,	NULL
R.	NULL
E.	NULL
Showalter	NULL
,	NULL
E.	NULL
W.	NULL
Moomaw	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
.	NULL

Crystal	NULL
structures	NULL
of	NULL
human	NULL
calcineurin	NULL
and	NULL
the	NULL
human	NULL
FKBP12-FK506-calcineurin	NULL
complex	NULL
.	NULL

Nature	NULL
378:641	NULL
.	NULL

Walker	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
P.	NULL
Saas	NULL
,	NULL
and	NULL
P.-Y	NULL
.	NULL

Dietrich	NULL
.	NULL

1997	NULL
.	NULL

Role	NULL
of	NULL
Fas	NULL
ligand	NULL
(	NULL
CD9SL	NULL
)	NULL
in	NULL
immune	NULL
escape	NULL
the	NULL
tumor	NULL
cell	NULL
strikes	NULL
back	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:4521	NULL
.	NULL

De	NULL
Maria	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
R.	NULL
Testi	NULL
.	NULL

1998	NULL
.	NULL

Fas-FasL	NULL
interactions	NULL
:	NULL
a	NULL
common	NULL
pathogenetic	NULL
mechanism	NULL
in	NULL
organ-specific	NULL
autoimmunity	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
19:121	NULL
.	NULL

Sakata	NULL
,	NULL
K.-m.	NULL
,	NULL
A.	NULL
Sakata	NULL
,	NULL
L.	NULL
Kong	NULL
,	NULL
H.	NULL
Dang	NULL
,	NULL
and	NULL
N.	NULL
Talal	NULL
.	NULL

1998	NULL
.	NULL

Role	NULL
of	NULL
Fas/	NULL
FasL	NULL
interaction	NULL
in	NULL
physiology	NULL
and	NULL
pathology	NULL
:	NULL
the	NULL
good	NULL
and	NULL
the	NULL
bad	NULL
.	NULL

Clin	NULL
.	NULL

Immunol	NULL
.	NULL

Immunopathol	NULL
.	NULL

87:1	NULL
.	NULL

Halliwell	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
C.	NULL
Gutteridge	NULL
.	NULL

1990	NULL
.	NULL

Role	NULL
of	NULL
free	NULL
radicals	NULL
and	NULL
catalytic	NULL
metal	NULL
ions	NULL
in	NULL
human	NULL
diseases	NULL
:	NULL
an	NULL
overview	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

186	NULL
:	NULL
1	NULL
.	NULL

Delneste	NULL
,	NULL
Y.	NULL
,	NULL
P.	NULL
Jeannin	NULL
,	NULL
E.	NULL
Sebille	NULL
,	NULL
J.-P.	NULL
Aubry	NULL
,	NULL
and	NULL
J.-Y	NULL
.	NULL

Bonnefoy	NULL
.	NULL

1996	NULL
.	NULL

Thiols	NULL
prevent	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
-mediated	NULL
T	NULL
cell	NULL
apoptosis	NULL
by	NULL
down-regulating	NULL
membrane	NULL
Fas	NULL
expression	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

26:2981	NULL
.	NULL

Subara	NULL
,	NULL
T.	NULL
,	NULL
K.	NULL
Fukuo	NULL
,	NULL
T.	NULL
Sugimoto	NULL
,	NULL
S.	NULL
Morimoto	NULL
,	NULL
T.	NULL
Nakahashi	NULL
,	NULL
S.	NULL
Hata	NULL
,	NULL
M.	NULL
Shimizu	NULL
,	NULL
and	NULL
T.	NULL
Ogihara	NULL
.	NULL

1998	NULL
.	NULL

Hydrogen	NULL
peroxide	NULL
induces	NULL
up-regulation	NULL
of	NULL
Fas	NULL
in	NULL
human	NULL
endothelial	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

160:4042	NULL
.	NULL

Williams	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Henkart	NULL
.	NULL

1996	NULL
.	NULL

Role	NULL
of	NULL
reactive	NULL
oxygen	NULL
intermediates	NULL
in	NULL
TCR-induced	NULL
death	NULL
of	NULL
T	NULL
cell	NULL
blasts	NULL
and	NULL
hybridomas	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

157:2395	NULL
.	NULL

Bauer	NULL
,	NULL
M.	NULL
K.	NULL
A.	NULL
,	NULL
M.	NULL
Vogt	NULL
,	NULL
M.	NULL
Los	NULL
,	NULL
J.	NULL
Siegel	NULL
,	NULL
S.	NULL
Wasselborg	NULL
,	NULL
and	NULL
K.	NULL
Schulze-Osthoff	NULL
.	NULL

1998	NULL
.	NULL

Role	NULL
of	NULL
reactive	NULL
oxygen	NULL
intermediates	NULL
in	NULL
activation-induced	NULL
CD95	NULL
(	NULL
APO-1/Fas	NULL
)	NULL
ligand	NULL
expression	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273:8045	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL

